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Oxycodone (OC) has been in use as an analgesic drug since 1917. Its analgesic potency is
similar to that of morphine, and it has been recommended for use in the treatment of
moderate to severe pain. The elimination of OC in humans is mainly hepatic, and
metabolism by both phase I and phase II reactions is involved. Cytochrome P450
dependent N- and O-demethylation are the most important phase I metabolic pathways, and
the metabolites are noroxycodone (NOC) and oxymorphone (OM), respectively.
The enzymes involved in the metabolism of OC are poorly described, and therefore the aim
of this study was to deterrnine the enzyme kinetics for the formation of NOC and OM, and
to identify which liver P450 isoform(s) are involved in these two metabolic reactions.
Enzyme kinetics were obtained for 6 CYP2D6 extensive metabolizers (EM) and 1
CYP2D6 poor metabolizer (PM) liver. OM formation exhibited two enzyme kinetics in
both the EMs and the PM. Ku values for the EMs were 143t84¡rM and 29.3!34.1mM
(mean+SD), while the PM had Kr,,r values of 277¡t"M and 26.7tttNl NOC forrnation had
single enzyme kinetics in most livers, and the K¡a was 4.07!3.92Í1tl[l4 (meantSD) with a
range of 1.52-12.9mM. Substantial variability in the intrinsic clearance (V,./Krur) through
the NOC pathway was observed (55-724 ¡llhrlmgprotein).
Using specific chemical and antibody inhibitors and CYP expressed enzymes, it was shown
that NOC formation is mainly dependent on CYP3A4, while CYP2D6 is the main isoform
involved in OM formation. However, at least one other enzyme is responsible for 4.1+3.3o/o
(mean+SD) of OM formation, and a minor CYP2C19 involvement cannot be excluded
from NOC formation. Environmental (CYP3A4) and genetic (CYP2D6) factors are likely
to contribute to variability in the analgesic response to oxycodone in patients with pain.
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The human body is constantly exposed to foreign substances (xenobiotics), which may
have various effects on physiological functions. Xenobiotics can be man-made or from
natural sources, and include drugs as well as unwanted chemicals such as toxins from
plants and animals, industrial chemicals and pollutants (Parkinson, 1996).
1.1.1 The role of biotrunsformøtion
Many xenobiotics entering the body are lipophilic, a feature that enables them to cross
bilayered lipid membranes such as the surfaces of the gastrointestinal and respiratory tracts.
However, these substances are also subject to reabsorption by the kidneys, which allows
them to remain in the body for an extended period of time. Consequently changes in
chemical properties are required to facilitate the elimination of these substances.
Xenobiotics are converted to forms that are more readily excreted by the kidneys; a process
referred to as biotransformation or metabolism (Parkinson, 1996; Correia, 1998).
1.1.2 Phøse I and phase II reactions
Xenobiotic biotransformations are generally divided into phase I and phase II reactions.
In phase I reactions a functional group is exposed (e.g. -OH, -NHz or SH) by hydrolysis,
reduction or oxidation to leave the molecule more hydrophilic. This is sometimes suff,rcient
to make the metabolite excretable by the kidneys, but most commonly they are metabolised
further by a phase II reaction.
The phase II reactions are often referred to as conjugations since they involve binding (via
a transferase enzyme) of endogenous compounds to the newly formed functional groups.
Phase II reactions include glucuronidation, sulfation, acetylation, metþlation, and
conjugation with glutathione or amino acids. Of these reactions, glucuronidation is the
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most coÍtmon. Some drugs possess functional groups that already make them suitable for
conjugation (-OH, -COOH), in which case the phase II reactions may occur without the
preceding phase I reaction. The products of phase II reactions are highly polar, a property
that makes them suitable for renal excretion (Parkinson,1996; Correia, 1998).
1. 1. 3 An ato mical distribution of biotran sfo rmin g en zym es
The enzymes involved in biotransformation of drugs are located in several tissues, such as
gastrointestinal epithelium, skin, nasal mucosa, lungs, kidneys, brain and other tissues,
although the liver contains the largest amounts of the common xenobiotic biotransforming
enzymes. 'Within the liver cells (and cells in most other organs), the enzymes are found
mainly in the endoplasmic reticulum or in the cytosol, but smaller amounts are also found
in mitochondria, nuclei and lysosomes (Parkinson, 1996).
Homogenization and differential centrifugation of liver tissue disrupts the endoplasmic
reticulum, which then forms microvesicles referred to as liver microsomes. Liver
microsomes possess high concentrations of xenobiotic-biotransforming enzyrnes, and arc
therefore commonly used to study the metabolism of drugs in vitro (Parkinson, 1996).
1.1.4 Cytochrome P450
Most phase I reactions are catalysed by the mixed function oxygenase system, which is
located in the endoplasmic reticulum of the cells (e.g. hepatocytes). CytochromeP450
enzymes are the main components of this system, and they have many important biological
functions (e.g. steroid synthesis). These enzymes are also involved in the biotransformation
of xenobiotics. Cytochrome P450 can be found in bacteria, plants, yeast and animals, a fact
indicating that the ancestral gene coding for this protein family has existed since early
forms of life developed more than 3.5 billion years ago (Nelsonet al., 1996).
Each individual cytochrome P450 isoenzyme consists of a single protein and a haem goup
as a prosthetic moiety (Evans, 1993; Chang andKam, 1999). In its reduced form
2
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cytochrome P450 binds CO, a complex that has a maximum light absorbance at 450nm.
Hence the derivation of the name of the enzyme (Correia, 1998).
The cytochrome P450 drug oxidation cycle (Figure 1) begins with the binding of a
substrate (e.g. drug) to the oxidized form of cytochrome P450 (Fe3*). This is then reduced
when an electron is received from NADPH reductase. The reduced complex of
cytochrome P450 (Fe2+) and substrate binds molecular oxygen and then receives another
electron from the NADPH reductase. The end products of the cycle are an oxidized

















Figure I The catalytic cycle ofdrug oxidation by cytochrome P450 (Correia, 1998).
This figure is reproduced from Basic and Clinical Pharmacology by Katzung (Appleton & Lange), and
has been printed with permission of The McGraw-Hill Companies 15rr' July 2001¡.
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1.1.4.1 Cytochrome P450 famìlíes and subfamilies
There are 17 known cytochrome P450 families in humans, which form 39 subfamilies
(Nelson, 2000). This is arl area that is currently subject to extensive research, and new
discoveries are frequent.
The general nomenclature for the cytochrome P450 enzymes is based on the sequence
similarities within the families and subfamilies. The prefix CYP designates cytochrome
P450 in all species (CY for cytochrome and P for pigmenÐ. P450 isoforms with more than
40%o amino acid homology are in the same family, which is designated by an Arabic
numeral (e.g. CYP2). Each family may consist of subfamilies, which have at least 55%
amino acid homology and are denoted by a capital letter (e.g. CYP2D). The individual
enzyme is denoted with an Arabic numeral at the end (e.g. CYP2D6), and is referred to as
an isoenzyme of CYP450. The genes associated with the enzymes are denoted after the
same system, but in italic (e.g. CYP2D6) (Nelson, 2000; Chang and Kam, 1999).
CYPI, CYP2 and CYP3 constitute more than 70Yo of the total hepatic P450s, and are
responsible for most xenobiotic metabolism (Wrighton and Stevens,1992).
Table 1 shows the function of the various CYP families that have been identihed in
humans, and it is based on the reviews by Nelson et al. (1996) and (Nelson,2000). Some of
the P450 isoenzyrnes important in drug metabolism will be discussed further in section
1.1.6.
1.1.5 Factors reguløting cytochrome P450 metøbolic cupøcity
CYP metabolic capacity may need to be considered when deciding on the drug dose and
the frequency of administration, in order to achieve the desired therapeutic effect. The
capacity of metabolism shows substantial inter-individual variability, and this can be due to







Retinoic acid hydroxylase important in developmentCYP26
Mitochondrial enzyme involved in vit. D degradationCYP24
Steroid biosynthesisCYP1 I, CYPI7, CYP19, CYP2I
Involved in bile acid synthesisCYPSB
Prostaglandin synthesrsCYPSA
Brain specific cholesterol hydroxylaseCYPTB
Cholesterol hydroxylase (bile acid biosynthesis)CYPTA
Thromboxane synthestsCYP5
Important in xenobiotic metabolismCYPI, CYP2, CYP3, CYP4
Table I Cytochrome P450 families and functions in human (Nelson,2000).
1. 1. 5. 1 Environmentøl factors
Drugs can inhibit or induce the activity of CYP isoforms. This can lead to clinically
significant drug-drug interactions when multi-drug treatment is necessary.
CYP inhibition can be competitive or non-competitive. A competitive inhibitor binds to the
same site on the CYP as the substrate, and may or may not be metabolised by the enzyme it
inhibits. Non-competitive inhibitors bind to a different binding site on the CYP. Reduced
drug clearance and an increased elimination half-life are the direct pharmacokinetic
consequences of inhibition of drug metabolism. The clinical consequences of CYP
inhibition depend on the type of inhibition, as well as the activity and toxicity of both the
parent drug and its metabolite(s). If a drug with a nanow therapeutic window accumulates
in the blood stream due to such an interaction, toxicity may occur (e.g.warfarin). Drugs
with active metabolites may show reduced effect if its metabolism is inhibited
(e.g. codeine). Conversely, drug interactions can sometimes be used intentionally in
medical treatment. An example of this is the ceadministration of CYP3A4 inhibitors,
5
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ketoconazole and/or erythromycin, with cyclosporine. Cyclosporine is an
immunosuppressant metabolised by CYP3A4, and its use is very costly. CYP3A4
inhibitors will increase the bioavailability and prolong the elimination half-life of this drug,
and therefore reduce the dosage and frequency of administration (Parkinson, 1996;
Touw, 1997).
Inducers of cytochrome P450s increase the rate of xenobiotic metabolism. The result is an
increased clearance and reduced elimination half-life, which is a problem clinically as
increased drug doses and more frequent drug administration are needed (Parkinson, 1996).
Great care must be taken when multidrug treatment regimens are necessary due to the
potential drug-drug interactions.
There are also examples of CYP450 activity being modulated by dietary factors. Grapefruit
juice inhibits the activity of CYP3A4 along the gastrointestinal tract (Bailey et al., 1994;
Lilja et a1., 2000). The result is a signihcantly increased bioavailability when CYP3A4
dependent drugs with high first metabolism aÍe administrated orally. Cruciferous
vegetables (e.g. cabbage) cause induction of CYPlA2 activity and inhibition of CYP2E1
activity (Yang et a1.,1992).
Other lifestyle dependent factors include cigarette smoking and alcohol. Cigarette smoking
induces the activity of CYP1A2, whilst chronic alcohol consume increases the activity of
CYP2EI (Glue and Clement,1999).
I. 1. 5. 2 Genetìc polymorphìsms
Genetic pol¡zmorphism is a genetic variation that can cause impairment of, for example,
enzymatic activity in certain members of the population. In order to call it a polymorphism,
the difference in DNA sequence has to be found in at least lo/o of the population
(Chang and Kam, 1999). Such polymorphisms are caused by genetic alterations, and the
result may be either a complete deletion of the enzyme or an alteration (usually reduction)
in metabolising capacity (Touw, 1997). This variability in enzyme expression may alter the
pharmacokinetics of a drug. Lack of metabolic activity may lead to accumulation of parent
drug and less formation of the metabolite(s). The consequence of this depends on the
activity of the parent drug and the metabolite(s). Accumulation of a drug that is active in its
6
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original form can raise the plasma concentration to a level higher than the therapeutic
range, which in turn can increase the incidence of side effects and toxicity ( e.g. sparteine).
If a metabolite is active and of importance for the drug's mechanism of action (prodrug),
reduced enzymatic activity will lead to insufficient effect of the drug (e.g. codeine)
(KroemerandEichelbaum, 1995; Touw, 1997; ChangandKam, 1999). Attention may
therefore need to be paid to the patient's genetic state when administering a drug.
The genetic polymorphism of drug metabolising pathways was first discovered due to
increased incidence of adverse effects in some patients when administering the drug at
standard recommended doses (Maþoub et a1., 1977; Edeki, 1996). The most studied
genetic polymorphism involving cytochrome P450 is the debrisoquine/sparteine
polymorphism, which was discovered about 25 years ago (Maþoub et al.,1977;
Eichelbaum et al.,l9l5). Several cytochromeP450s have now been shown to be subject to
polymorphisms, and the individual polymorphisms involved in drug metabolism will be
discussed in section 1.1.6.
Genotyping and phenotyping make it possible to group individuals with respect to the
various drug metabolising genetic polymorphisms. Genotype is usually assessed using a
method based on polymerase chain reaction (PCR), which involves amplification of the
DNA region encoding for the enzyme mutation by use of complementary primers.
Phenotype is determined by estimating enryme activity for a selected probe substrate that
is metabolised by the particular enzyme. Both methods have advantages and disadvantages.
Genotyping is increasingly popular since the results provided are accurate and detailed, but
the method is costly and the genotype does not always reflect function. Phenotyping gives
a functional assessment of the enzymatic activity, taking environmental factors influencing
enzyme activity into account (e.g. drug interactions). However, the use of a probe drug
introduces the potential of adverse effects and concerns with regard to invasiveness and
inconvenience. Furthermore, the genotype remains uncertain (Nebert, 2000;
Kroemer and Eichelbaum, 1995; Streetman et al., 2000).
Individuals are characterized as poor metabolizers (PM) or extensive metabolizers (EM)
with respect to the polymorphically expressed enzyme (e.g. CYP2D6). Another group,
ultra rapid metabolizers (URM), has also been discovered for CYP2D6 (Touw, 1997).
7
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Substantial differences in genetic polymorphisms have been found between inter-ethnic
populations. For example, only 7Yo of a Japanese population is PM with respect to
CYP2D6, while the percentage in a Caucasian population is 5-10 (Daly et a1.,I996;
Edeki, 1996). Another typical example is the CYP2Cl9 polymorphism. Poor metabolizers
for this enzyme represent only 2-5o/o in Caucasian populations, whereas the frequency for
Asian populations is as high as 23Yo (Bertilsson,I995; ChangandKam, 1999). Many
known genetic polymorphisms have been the subject of population studies, and knowledge
in this area is increasing rapidly.
Genetic polymorphisms may play a role in the development of various disease states, such
as cancer (e.g.CYP2E1), adrenal hyperplasia (CYPlA2) and Parkinson's disease
(e.g.CYP2D6). The evidence for these relations is not conclusive and further investigation
is needed to support current research (Chang and Kam, 1999). Knowledge about the
association between disease and CYP genotypes may help to prevent marry fatal diseases,
since chemical exposure sometimes contributes to the disease onset.
1.1.5.3 Gender, øge and disease states
Gender-related differences in CYP450 metabolic capacity can be fornd in several species.
This is particularly prominent in rats, where male animals have higher rates of xenobiotic
metabolism than females (Mugford and Kedderis, 1998). The difference between genders
is less prominent in humans. When a difference is present, females are generally found
with higher plasma concentrations of the drug than males after equivalent doses, although
little consistency is seen between studies in this area. For example, several studies have
indicated that CYP2C19, CYP2D6, and CYP2E1 have higher metabolic capacity in men,
whereas drugs metabolised by CYP3A4 seem to be eliminated faster by women (Mugford
and Kedderis, 1998; Tanaka, 1999a). However, these gender-related differences cannot be
related directly to differences in CYP450 activity. Several in vitro studies have shown that
expression of CYP450 isoforms relevant for xenobiotic metabolism is the same in both
genders (George et al., 1995; Shimada et a1.,1994). The aetiology of gender-related
differences in xenobiotic metabolism is probably due to CYP induction and dowrr
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regulation, and includes differences in environmental exposure (e.g. alcohol consumption
and smoking) as well as the influence of androgenic hormones (Touw, 1997;
Tanaka, 1999a). Other pharmacokinetic parameters than metabolism (e.g. absorption and
protein binding) will also alter the fate of a drug in the body. It is therefore difficult to
correlate gender-related differences in drug pharmacokinetics to metabolism alone
(Tanaka, I999a; Mugford andKedderis, 1998).
In vivo studies using probe drugs for various CYP450 isoforms indicate that metabolic
capacity changes between the various stages of life. Generally the activity is low at birth,
increases until it peaks in young adults, and then decreases with old age (Tanaka, 1998).
The aging pattern for different enzymes varies. It has been shown in population studies that
CYPlA2 capacity decreases above the age of 55, while CYP2D6 capacity decreases above
the age of 65. These differences indicates that agerelated changes in metabolic capacity
can be correlated directly to the specific CYP450 isoforms, although other factors may also
contribute to pharmacokinetic changes with age (e.g.hepatic blood flow) (Touw, 1997;
Tanaka, 1998).
Several disease states can influence drug metabolising capacity. Fat accumulation in the
liver, alcoholìc, viral- or drug-induced hepatitis, alcoholic cirrhosis and biliary cirrhosis are
some examples. These conditions impair the function of drug metabolising erìzymes, which
in turn affects drug elimination. Liver cancer is also associated with reduced metabolic
capacity. This is mainly caused by reduced CYP450 content. Poisoning with certain heavy
metals (e.g. lead) has been shown to impair enzyme activity or cause defective formation of
enzymes. In both situations the consequence will be reduced metabolic capacity
(Correia, 1998).
1.1.6 Cytochrome P450 enzymes of relevanceÍor human drug metabolism
The majority of commonly used drugs ate metabolised by a limited number of




CYP2 constitutes about 35Yo of total hepatic P450, and it is the family that contains the
highest number of subfamilies (Lewis, 1998). CYP2D6 is an important isoenzyme from the
CYP2 family since it has been related to the metabolism of more than 60 different drugs,
including several tricyclic antidepressants, selective serotonin reuptake inhibitors, analgesic
drugs, anti-arrhythmic drugs, beta-blockers, anti-hypertensives and others. CYP2D6
accounts for approximately 2% of total hepatic P450 (Touw, 1997; Lewis, 1998;
Chang and Kam, 1999; Nebert et al., 1999).
CYP2D6 is subject to genetic polymorphism, and drugs metabolised by CYP2D6 arc
therefore at high risk of adverse effects. This particular polymorphism has been well
studied since many drugs are metabolised by CYP2D6, and reduced metabolism can be
manifested in 5-I0Yo of Caucasians (KroemerandEichelbaum,1995; Dalyet a1.,1996).
Codeine is one commonly used d*g that is highly influenced by the CYP2D6
polymorphism. This drug exerts its effect via an active metabolite (morphine), and the
pathway is mediated by CYP2D6 (Chen et al., 1988). Lack of an antinociceptive effect of
codeine is seen in PM with respect to CYP2D6 (Sindrup and Brøsen, 1995).
The gene encoding for CYP2D6 is located on chromosome 22 (Eichelbaum etal.,1987),
and many mutations of this gene have been discovered. Although five alleles represent over
95Yo of the PM variants (Dalén et al., 1999), 70 allelic variations had been described up to
June 2000 (Oscarson,2000). CYP2D6*I is representing the normal functioning enzymq
and this allele is also referred to as the "wildtype" (Sachse et a1.,1997). The most frequent
alleles representing PM with respect to CYP2D6 are CYP2D6*3 (frame shift mutation),
CYP2D6*4 (splicing mutation), CYP2D6*5 (gene deletion), CYP2D6*7 (base pair change
mutation) and CYP2D6*6 (frame shift mutation) (Daly et al., 1996), with CYP2D6*4
counting for about 75%o of the PMs in Caucasians (Bertilsson, 1995). The overall result
from the various mutations is no function or decreased effect of the eîzyme in
homozygotes (Daly et al., 1996). The mutated genes are recessive, and the PMs are
homozygous for any two defective alleles. EMs can be either heterozygous or homozygous
for the dominant functioning allele (Touw,7997).
t0
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Another allele, CYP2D6*10, represented3SYo of CYP2D6 alleles in a Japanese population,
which is similar to that found in other studies on Asian populations (Nishidaet al., 2000).
This allele has been reported to represent only about 2% in Caucasians
(Griese et a1., 1998). CYP2D6*10 results in reduced enzyme activity. Consequently the
average EM in Asian populations has lower CYP2D6 activity than the average EM from a
Caucasian population (Bertilsson,1995; Nishida et al., 2000).
Gene duplication or amplification can occur for the CYP2D6 gene, resulting in individuals
with ultrarapid metabolism. Up to twelve extra copies of the CYP2D6*2 allele have been
described and related to high CYP2D6 activity. About l-2o/o of Caucasians are classified as
ultra rapid metabolizers (URM) (Dalén et al., 7999), but substantial interethnic variation
has been reported. Aklillu et al. (1996) found a high frequency (29%) of individuals with
duplicated or multi-duplicated CYP2D6 genes in an Ethiopian population of 122 subjects.
Phenotyping of CYP2D6 is usually carried out with dextromethorphan as a probe drug
since this drug has a wide safety margin. CYP2D6 mediated O-demethylation is the rate
limiting step in dextromethorphan metabolism, and since dextromethorphan and its
metabolites are excreted in the urine, CYP2D6 phenotype can be identified by calculating
the urinary metabolic ratio (dextromethorphan/dextrorphan at 8 hours). Several other drugs
have also been used to phenotype for CYP2D6 activity, for example debrisoquine and
sparteine, although their availability and safety have limited their use (Streetman et
al., 2000).
1.1.6.2 CYP3A4
CYP3A accounts for about 30Yo of the total hepatic P450 and 70o/o of the gut wall P450 in
humans. Four genes, CYP3A3, CYP3A4, CYP3A5, and CYP3AZ control this family, but the
latter is only present in utero. CYP3A3 and CYP3A4 have an amino acid similarity of 97o/o,
and are therefore difficult to separate. In spite of this, CYP3A4 has shown a greater
expression than CYP3A3 in the human liver, and it is generally accepted that CYP3A3 is
included when referring to CYP3A4. CYP3A5 is only expressed in about 25-30% of liver
samples, and is generally enhancing the metabolism of drugs that are metabolised by
CYP3A4. (Wrighton and Stevens,1992; Chang and Kam, 1999).
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CYP3A4 metabolises more than 50 Vo of all drugs (e.g. several opioid analgesics,
erythromycin, warfarin, diazepam), as well as several endogenous compounds (e.g.
testosterone, oestradiol, progesterone). This CYP isoform has therefore been subject to
extensive research (Benet et al., 1996; Nelson, 2000).
Substantial inter-individual variability in metabolising capacity is seen for CYP3A4 (20-40
fold - in vitro studies) (Ball et al, 1999), but the mechanisms behind the variation remains
to be fully clarified. The expression of CYP3A4 is highly inducible by a wide range of
xenobiotics, and this is believed to be the main reason for the inter-individual variability.
Recent research on CYP3A4 regulation has shown that nuclear hormone receptors, named
pregnane X receptors, are of major importance in the induction of CYP3A4. These
receptors bind to xenobiotic response elements in the CYP3A4 promoter region, and are
activated by known CYP3A4 inducers (Jones et a1.,2000). No evidence of a functionally
important allelic variability is found in the coding region of the CYP3A4 gene, and the
population distribution after phenotyping is unimodal (Guengerich, 1999). A genetic
variation has been found in the 5'promotor region of the CYP3A4 gene, and there is a clear
inter-racial difference in the frequency of this variation. However, there are no functional
differences between the two genotypes (Ball et a1.,1999; Wandel et a1., 2000).
Many probes have been usecl to phenotype CYP3A activity. CYP3A plays a major role in
the 6B-hydroxylation of endogenous cortisol, and the ratio of 6B-hydroxycortisol to free
cortisol in urine has therefore been used as a measure of CYP3A activity. However, the
validity of this test has been questioned since the correlation is poor between this method
and other accepted phenotyping methods. Another approach to CYP3A phenotyping is the
erythromycin breath test. CYP3A4 selectively Ndemethylates erythromycin. When [toC]-
,N-metþl erythromycin is used, the cleaved carbon of the metþl group is expired as
tac}z, and the extent of CYP3A 4 activity can be measured as radioactivity. The
erythromycin breath test provides a rapid approach to CYP3A4 phenotyping, but CYP3A5
activity is not measured, and the test only reflects the hepatic CYP3A4 activity since the
probe is intravenously administered. The most reliable of all reported phenotyping methods
for CYP3A is the use of oral midazolam. Midazolam can be safely administrated orally and
intravenously, and it is metabolised by CYP3A4 as well as CYP3A5. CYP3A activity can
be measured as an hydroxylation ratio or total plasma clearance. The disadvantage of this
12
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method is the inconvenience of multiple intravenous blood samples (Thummel and
'Wilkinson, 
1998; Streetman et a1.,2000).
1. 1. 6. 3 CYP2C9/CYP2C 1 9
The CYP2C subfamily comprises about 20Yo of the total hepatic CYP450, making it the
largest subfamily within the CYP2 group (Lewis, 1998). There are four known members of
this family in humans; CYP2C8, CYP2C9, CYP2C18 and CYP2C19 (Nelsonet al., 1996).
CYP2C8 and CYP2C18 have an amino acid homology of 76%o, while the homology
between CYP}C9 and CYP2C19 is 91% (RichardsonandJohnson,l996). Within the
CYP2C family, CYP2C9 and CYP2C19 are the most important. The CYP2C family
metabolises a wide range of drugs, but despite the high sequence similarity little overlap in
substrate specificity is seen between the CYP2C isoforms (Miners and Birkett, 1998).
CYPZC9 is considered to be one of the most important drug-metabolising enzymes in
humans. Examples of drugs metabolised by CYP2C9 are tolbutamide, fluoxetine,
phenytoin and warfarin. CYP2C9 is induced and inhibited by many drugs. Rifampicin and
barbiturates are examples of CYP2C9 inducers, while sulphaphenazole is a potent
inhibitor. The latter is used in vitro and in. vivo to cletermine CYP2C9 involvement in
metabolism of drugs (Miners and Birkett, 1998). Three different alleles of CYP2C9 have
been found, two of which result in decreased metabolism (Oscarson,2000). The PM
phenotype has shown to be less than lo/o in Caucasian populations (Miners and Birkett,
1ee8).
CYPZCI9 is involved in the metabolism of S-mephenytoin, proguanil, diazepam and many
other commonly used drugs. This CYP2C isoform has been well studied since it is subject
to a genetic polymorphism that impairs 4'-hydroxylation of S-mephenytoin. The PMs with
respect to this enzyme represent about 2-5o/o of Caucasians (Nebert et al.,1999), while the
incidence in Asian populations has been reported to be up to 23o/o (Bertilsson, 1995). Seven
different mutations that can cause this polymorphism have been registered by February
2000, all of them resulting in no enzyrnatic activity in vivo. The two most common alleles
responsible for impaired enzyme activity are CYP2C19*2 (splicing mutation) and
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CYP2CI9*3 (stop codon) (Oscarson,2000). The latter has only been found in Asian
populations (Nebert et aI.,1999).
Mephenytoin has been the standard drug in phenotyping for CYP2C19 (urinary ratio
between S- and R- enantiomers), but adverse effects and problems with long-term sample
stability have reduced its use. Omeprazole has been tested as an alternative to
mephenytoin. CYP2C19 phenotype is given by the omeprazole hydroxylation index, which
is the ratio between omeprazole and 5'hydroxyomeprazole in serum 2-3 hours after an oral
dose of omeprazole. However, the reliability of omeprazole phenotyping in non-healtþ
individuals, as well as the optimal omeprazole dosing has not been fully investigated.
Therefore it remains unclear which drug is the preferred probe for CYP2C19 phenotyping
(Streetman et al., 2000).
1.1.6.4 CYPLA2
CYP1 is also involved in xenobiotic metabolism, and the most studied isoform, CYP1A2,
accounts for approximately l3o/o of the total hepatic P450. This isoform of CYP450 is only
found in the liver, and its endogenous functions are unclear. Xenobiotics metabolised by
CYPlA2 include caffeine, tertiary amines (e.g. amitriptyline, imipramine) and clozapine.It
has also been related to the metabolism of polycyclic aromatic compounds, a process
associated with cancer (Touw, 1.997; Chang and Kam, 1999).
CYPlA2 is highly sensitive to induction (e.g. cigarette smoke). Consequently inter-
individual variation in metabolic capacity is seen, but no genetic polymorphisms have been
reported (Touw, 1997; Chang and Kam,1999). Caffeine has been used as a probe substrate
to assess metabolic capacity of CYPIA2 (Streetman et al.,2000).
1.1.6.5 CYP2El
CYP2EI accounts for 7o/o of total hepatic P450, and it is involved in the metabolism of
many organic solvents and alcohols as well as several structurally diverse drugs. These
include paracetamol, many volatile anaesthetics (e.g.diethyl ether) and chlorzoxazone.
t4
CYP2EI is also toxicologically important since it appears to activate a large number of
suspected carcinogens (Chang and Kam, 1999; Touw,1997; Wrighton and Stevens,1992).
CYP2El activity varies considerably between individuals. One reason for this is induction,
and ethanol is known to be a potent inducer. Genetic pol¡rmorphism of CYP2El has also
been reported, and the mutated alleles correlate with increased risk of diseases associated
with xenobiotic exposure, such as nasopharyngeal cancer (Daly et a1.,1998; Nelson, 2000).
The allele frequency within different ethnic populations is yet to be determined
(Tanaka, 1999b). Chlorzoxazone is used as a probe to assess CYP2EI activity, although its
use can be questioned since other enzymes may be involved in the metabolism of this drug
(Streetman et a1., 2000)
1. 1. 6. 6 S u b s t r øt e sp e c ifìc ity an d st r u ct u r e - ø ct iv ity r el øt io n s h ip
Studies have shown that there are relationships between substrate molecular structure and
CYP isoform involvement. It is therefore possible to predict CYP isoform involvement if
the molecular structure of a substance is known.
CYP2D6 metabolises drugs with a basic nitrogen atom, which usually contains an aromatic
ring. The distance hetween the basic nitrogen ancl site of oxiciation is 5, 7 or 10 Ä.
Substrates of CYP2D6 aÍe also relatively hydrophilic (de Groot et a1.,1999;
Lewis et a1., 2000). CYP3A4 substrates are structurally diverse. They generally have a high
molecular volume, and are relatively lipophilic. CYPIA2 metabolises planar molecules
with medium molecular volume. CYP2E1 substrates are also relatively planar, but a low
structural volume characteizes these substrates. CYP2C9 metabolises substrates that are
weakly acid and lipophilic, while substrates to CYP2C19 are neutral or weakly basic and
moderately lipophilic (Lewis et a1., 2000).
1.1.7 Determinution of CYP450s
Knowledge about the enzymes involved in a drug's metabolism is important in clinical
pharmacology. Interactions with other drugs (i.e. drug-drug interactions) metabolised by
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the same enrytme must be avoided if possible, and multi-drug treatment programs are
common clinically. The influence of genetic polymorphisms may also need to be taken into
account if the involved enzymes are known. Thus severe adverse effects from drugs may
be avoided.
Several approaches are used to determine which P450s are involved in the metabolism of a
drug. These include in vitro studies as well as clinical assessment methods. Standardizedin
vitro techniques for the determination of CYP450 involvement include:
l) correlating the formation rate of the test drug with that of enzyme-specific
substrates in well-characteized tissue (for example in a panel of human liver
microsomes)
2) selective inhibition or stimulation in enzyme containing tissue (chemical inhibitors
or inducers with selectivity for specific enzymes; e.g. ketoconazole inhibits
CYP3A4 activity)
3) immunoinhibition (enzyme-specific antibodies used for inhibitory studies)
4) expressed or pwified enzymes (individual CYP450 isoforms cloned from yeast,
bacterial or insect cells, or purif,red from human liver cells)
There are advantages and disadvantages in the use of all these methods, and a combined
approach is recommended (Halpert et al., 1994; Glue and Clement,1999).
It is essential to use concentrations of the chemical inhibitors that provide specihcity in
action, since chemical inhibitors generally lose their specificity at increasing concentrations
(Newton et a1., 1995). Chemical inhibitors are often used initially, followed by the use of
antibodies and expressed enzymes. The latter two provide more accurate information on
CYP450 involvement, while an initial chemical inhibition study can help in the selection of
antibodies and expressed enzymes. This will be the approach adopted in this project.
Co-administration of known enryme specific inhibitors can provide clinical information on
CYP450 involvement (Glue and Clement, 1999). It has been proposed that clinically
significant changes in drug concentrations only occur if the inhibited enzyme is responsible
16
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for elimination of more than 50Yo of the drug. This does not apply if the therapeutic




1.2.1 Opioids - dejìnition and classiJication
Opioids are arly substance that produces effects similar to that of morphine, and that are
blocked by the nonspecific opioid receptor antagonist, naloxone. This includes naturally
existing opium alkaloids extracted from the opium poppy (Papaver Somniferum), semi-
synthetic derivatives structurally related to these (e.g. oxycodone), pharmacologically
similar synthetic surrogates (e.g. methadone) and various neuropeptides (e.g. enkephalin)
(Rang et al., 1995b; Way et al., 1998).
Opioid drugs include full agonists (e.g. morphine), partial agonists (e.g. pentazocine),
antagonists (e.g. naloxone) and mixed agonist-antagonists (e.g. buprenorphine). The latter
have different effects depending on the receptor to which they bind.
The main chemical structural group within the opioid class is that with a similar structure
to morphine; the phenanthrenes. Besides morphine, this group includes several of the
strong and weak opioid agonists commercially used for treatment of pain (e.g. codeine and
oxycodone) as well as several opioid antagonists (e,g. naloxone and naltrexone)
(Way et al., 1998).
1.2.2 Mechønism of actíon - opioid receptors
Opioid agonists exert their effects on target proteins referred to as opioid receptors. These
receptors are mainly located in the central nervous system (CNS), but a smaller fraction
can also be found in certain peripheral tissues. Central effects of opioids are mediated at
multiple sites within the CNS. The receptors have been located in the dorsal horn of the
spinal cord, in ventral caudal thalamus of the diencephalon, in the periaqueductal grey of
the midbrain, as well as in the rostral ventral medulla. Opioids directly influence the
transmission of pain and indirectly modulate pain transmission via descending inhibitory
pathways (Way et al., 1998).
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Three types of opioid receptors are known to exist; p(mu), ô(delta) and r(kappa) (IUPHAR
classif,rcation of opioid receptors). These are themselves heterogeneous, with each of them
divided into subtypes (Dhawan et a1.,1996).
Opioid receptors are G-protein coupled receptors. Following binding of an opioid agonist
to the receptor, adenylate cyclase, a membrane protein that converts inhacellular AMP to
cAMP (cyclic adenosine-3'5'-monophosphate), is inhibited. This in turn reduces the
intracellular levels of oAMP, which either activates K*-channels or closes voltage-gated
Ca2*-channel. Opening of K*-channels hyperpolaize the neuron and stops the impulse
transmission, while suppression of Ca2*-currents reduces neurotransmitter release in
presynaptic nerve terminals. Both mechanisms are inhibitory to the transmission of nerve
signals, and can affect afferent neurons directly or indirectly. The latter involves an
increase of activity in descending inhibitory pathways via interneurons in the brain
(Reisine and Pasternak,1996; Bourne, 1998; Way et al., 1998)
Physiological effects from an opioid or an endogenous opioid peptide depend on their
affinity for the different receptors. The antinociceptive effect of the opioids is mediated
mainly through the opioid p-receptor, and the affinity to this receptor is usually related to
the analgesic potency of the drug. r- and ô- receptors can also be involved in analgesia, but
to a lesser extent than the p-receptor and mainly at the spinal level (Rang et a1., 1995b). No
clinically available drugs act exclusively on the r- and ô- receptors.
1.2.3 Opioid efficts and clinicøl use
Analgesia, euphoria, sedation and respiratory depression are the principal effects of opioids
(V/ay et al., 1998). These are all central nervous system effects, although the respiratory
depression has been proposed to have a peripheral component (Wayetal., 1998; Yeadon
and Kitchen, 1989; V/illette and Sapru, 1982).
Other CNS-mediated effects include nausea, miosis and suppression of the cough reflex.
Nausea (often followed by vomiting) is mediated by activation of brain stem
chemoreceptors, and it is one of the most common and troublesome side effects after intake
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of opioids. Miosis (constriction of the pupils) is an important diagnostic parameter in
opioid misuse and overdose.
The most important peripheral effect of opioids is reduction of gastro-intestinal (GI)
motility, which results in constipation. This is due to high levels of opioid receptors in the
GI tract, but central mechanisms are also involved (V/ay et a1., 1998)
Opioids are primarily used in the treatment of pain, and according to V/HO (World Health
Organization) recommendations they should be used in pain treatment when non-opioid












Table 2 Common opioid analgesics $ryHO, 1996; Way et al., 1998)
Morphine is the most commonly used opioid for moderate to severe pain, and as a result of
extensive experience with this particular drug it is often used as a reference drug when
assessing other analgesic drugs. Previously reported studies on the analgesic activity of
opioid agonists (e.g. oxycodone) have usually been comparative studies against morphinc.
Opioid drugs have been used for recreational purposes for thousands of years (opium), and
misuse remains a problem in modern society. The opioid misuse is reinforced by the high
addictive potential of the opioid drugs, and withdrawal syndrome becomes evident in the
absence of opioids in addicted individuals. Several opioid drugs (e.g. methadone) are used
in the treatment of opioid withdrawal. This therapy is referred to as opioid substitution, and
in addition to removing the withdrawal symptoms, it aims to bring the subjects back to a












Opioid drugs are also used as cough suppressants (e.g. codeine) and to control diarrhoea
(e.g. diphenoxylate) (Way et al., 1998).
1.2.4 Tolerønce to opioids ønd opioid rotation
Variability in patient response to opioid analgesics is common. Occunence of adverse
effects and tolerance is also frequently seen when opioid drugs are used in the tredment of
pain (Ashby et aL,1999). Tolerance can occur towards the desired effects (analgesia) as
well as the adverse effects; the latter being a favourable situation as the therapeutic window
is widened. Analgesic tolerance is apparent when increased doses are needed to maintain
the same analgesic potency over time. Escalating doses may result in an increase of side
effects and toxic potential. This situation often expedites a change in treatment regimen
(Mercadante, 1999).
There is substantial evidence for cross-tolerance between opioids. This is when tolerance
develops to one opioid agonist and concomitantly causes tolerance to other opioids
(Mercadante, 1999). However, clinical data show that patients can be successfully
transferred from one opioid to another, a situation referred to as opioid rotation or opioid
substitution (Ashby et a1.,1999; MacDonald et al., 1993; Sjøgren et al., 1994;
Mercadante,l999). Opioid rotation can be successful since the cross-tolerance is
incomplete.
In conclusion, clinicians need therapeutic options for the management of pain, and another




1.3.1 Oxycodone - hístory ønd ase
Oxycodone (OC) is a semi-synthetic derivative of thebaine, which is a naturally occurring
opium alkaloid. Oxycodone has been used since l9l7 (Kalso and Vainio, 1990), and it is
available both in combination with other analgesics, for example paracetamol
(e.g. Percocet @) or aspirin (e.g. Percodan @), and as a separate drug (e.g. Endone @)
(Martindale, 1999; MIMS Annual, 2000). It has been recommended as a drug for use in
moderate to severe pain (Pöihiä et al., 1993; WHO, 1996).
Oxycodone is most frequently administered in tablet form, but rectal suppositories
(e.g. Proladone @) are also available. A controlled-release formulation of oxycodone
(e.g. OxyContin @) has recently been introduced to the market in Australia. This provides a
longer lasting effect and greater administration intervals, which is particularly
advantageous for patients with chronic pain (MIMS Annual, 2000; Hagen andBabul,1997;
Kaplan et al., 1998). Parenteral formulations of oxycodone are not available on the market
(Martindale, 1999).
1.3. 2 Structure ønd Physícochemicøl properties
Oxycodone (Figure 2) is usually derived from thebaine, but it can also be synthesized by








Figure 2 Chemical structure of oxycodone (C-atoms numbered)
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The chemical name of oxycodone is 4,5cr-epoxy-14-hydroxy-3-methoxy-I7-
methylmorphinan-6-one (V/einstein and Gaylord 1979), but it is also referred to as 7,&
dihydro- 1 4-hydroxycodeinone (Martindale, 1999).
Oxycodone has the formula C1sH2¡NOa (My¿1:315.36). It is a weak base (pKa:8.5) that
exists in two tautomeric forms. Oxycodone is usually administered as the hydrochloride
salt, which has the formula ClsH22ClNOa (My¡1:351,.82). Oxycodone has also been used as
the terephthalate salt and as a pectinate salt in pharmaceutical formulations. Oxycodone in
its free base form is soluble in alcohol, chloroform and dichloromethane, but almost
insoluble in ether, water and sodium hydroxide (Budavarietal. 1989; Pöihiä etal.,L993;
Brauer and Ralfkiær, 1998).
A drug's lipid solubility is an important determinant of its pharmacokinetic characteristics.
Rate and extent of absorption from the gut, penetration of the blood-brain barrier and
penetration into other organs can all be predicted from the drugs lipid solubility. This
parameter is also an important determinant of how the drug should be formulated (oral
versus parenteral).
Different approaches have been used to assess the lipid solubility of oxycodone. Pöyhiä
and Seppälà (1994) compared the lipid solubility of oxycodone to other opioid drugs using
three previously described in vitro methods; the shake-flask method for partition of drug
between tris-buffer and n-octanol, solubility in human fat, and reversed phase high
performance liquid chromatography (van de Waterbeemd and Testa, 1987; Leo et aI., 7971;
Rosenberg et al., 1986). All three methods gave the same lipid solubility for oxycodone
compared to the other drugs tested. The lipid solubility of oxycodone was shown to be
relatively low, and close to that of morphine with the apparent partition coefficients (Pupp)
being 0.7+0.3 and 0.5+0.2, respectively. This is in accordance with Roy and Flynn (1988)
and Mahjour et al. (1989) who both found the Puoo of morphine to be 0.7. Plummer et al.
(1990) found the Puoo of oxycodone and morphine to be t .7 and 1.0, respectively.
Several other opioids with similar structures to oxycodone (Figure 3) have been well
investigated, and predictions about oxycodone pharmacokinetic and pharmacodynamic









Figure 3 Chemical structures of oxycodone and closely related phenanthrene opioids.
Codeine and morphine are the most studied of these drugs. Codeine has an active
metabolite (morphine) that is responsible for the effect of the drug, and a similar
mechanism of action has been proposed for oxycodone due to the structural similarities
(Sindrup and Brøsen, 1995; Cleary et al., L994). Details about this will be discussed later in
this chapter. Dihydrocodeine and hydrocodone are other opioids with closely related
structures. Hydrocodone only differs from oxycodone in the lack of an hydroxyl group at
C-14 (Rang et a1., 1995b; Reisine and Pasternak,1996).
1.3.3 Pharmøcology of oxycodone
1.3.3. 1 Receptor binding
The analgesic effect of opioid drugs has been related to their opioid p-receptor affinity (see
section 1.2.2).
The binding affrnity of oxycodone to the opioid ¡r-receptor has been studied in radio
receptor assays. Kalso et al. (1990) found that the p-receptor affinity of oxycodone is 1/10
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compared to that of morphine when 3H-dihydromorphine and 3H-naloxone were used as
radio-ligands. Oxycodone p-receptor affinity compared to that of morphine was only ll40
in a study by Chen et al. (1991a). They used I{-DAMGO as the radio-ligand.
Oxycodone binding aff,rnity to ô- and r-receptors has not been well described in the
literature.
1. 3. 3. 2 Anímøl antínociception
Ross and Smith (1997) showed that the antinociceptive effect of oxycodone in rats involve
binding of oxycodone to r-receptors. Maximum antinociception was seen after 5-7 minutes
when oxycodone was administered intracerebroventricularly. In this initial phase the
antinociception could be related directly to oxycodone, since first-pass metabolism, and
thereby formation of active metabolites, was avoided. The antinociceptive effect of
oxycodone was attenuated completely in rats if the specific r-receptor-antagonist nor-
binaltorphimine was pre-administered. In contrast, when the p-receptor selective
antagonist naloxonazine was administered prior to oxycodone, the antinociceptive effect of
oxycodone was not attenuated until after the initial phase (15 minutes), and the duration of
action was only shortened from 90 to 60 minutes. Interestingly the antinociceptive effect of
morphine was unaffected by the r-receptor-antagonist, whereas complete attenuation of
nociception was seen with the p-receptor antagonist. These results suggest that oxycodone
has an aff,rnity to the opioid r-receptor in rats, and that the p-receptor binding may not be
the only determinant of analgesia. However, the results cannot necessarily be related to
humans, and further studies are therefore needed to investigate the relationship betweenr-
receptor binding and oxycodone antinociception in humans.
1.3.3.3 Physiological efficts of orycodone in man
The effects of oxycodone are the same as for opioids in general (sectionl.2.3), with an
analgesic potency equivalent to that of morphine (Kalso et al., 1991; Beaver et a1., 1978b).
The analgesic potency of oxycodone is discussed in detail in section 1.3.5.
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Adverse effects of oxycodone seem to be similar, but milder, to those of morphine and
other comparable opioids. Leow et al. (l992alb) found that drowsiness and light-
headedness are the most frequently reported side effects. Nausea, vomiting, abdominal
pain, urinary retention, dry mouth, headache, nervousness, paresthesia, ear discharge,
hypotension and pruritus have also been noted (Leow etal.,l992a/b; Benziger et al.,
1997). Curtis et al. (1999) showed that patients receiving oxycodone had a higher incidence
of headache comparing with patients on morphine. Another study indicated that
constipation might be more frequently seen with oxycodone compared to morphine, and
that there is no significant difference in incidence of nausea between the two drugs
(Heiskanen and Kalso, l99l). In contrast to this, Pöihiä et al. (1993) found that nausea is
not commonly observed. They also reported an equivalent addictive potential to morphine.
Furthermore, less delirium is experienced with oxycodone compared to morphine
(Maddocks et al., 1996).
1.3.4 Pharmacokinetics of oxycodone
The fate of a drug in the body has an impact on drug effect. It is therefore important to have
knowledge about the pharmacokinetic properties of a drug.
1. 3. 4. 1 Bio availability
One advantage of using oxycodone is its high oral bioavailability. Several studies have
investigated the bioavailability of oxycodone after oral and rectal administration.
Beaver et al. (1978a) showed that oxycodone retained at least half of its analgesic potency
when it was administered orally compared to equivalent intramuscular injections.
Kalso and Vainio (1990) studied the eff,rcacy of oxycodone and morphine in patients with
cancer pain (n:19), and found the assumed bioavailabilities (ratio of oral and intravenous
dosing) of oxycodone and morphine to be 58 (3V17)o/o and38 (17-54) oá, respectively.
The latter is in accordance with Osborne et al. (1990) who found that morphine had an oral
bioavailability of 19-30 %. Another study, comparing single intramuscular and oral doses
of oxycodone, showed that the bioavailability of oxycodone was 60t20 % (Pöihiä et a1.,
1992). In this study the bioavailability data were based on oxycodone plasma
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concenffations. Leov/ et al. (I992a) also determined bioavailability of oxycodone on the
basis of oxycodone plasma concentrations. They found a mean oral bioavailability of 87o/o
in cancer patients (trl2), the highest oral bioavailability reported for oxycodone, but the
results showed a substantial inter-individual variability (28-139 %). Finally, a study
comparing oral and rectal administration routes to intravenous administration of oxycodone
in post-operative patients (n:I2) showed a bioavailability of 42+7.5Yo and 47+72.0 o/o for
the oral and rectal routes, respectively (Leow et a1., 1992b). These results were also based
on oxycodone plasma concentrations.
Wide variation is seen in the results from the bioavailability studies on oxycodone. One
explanation for this might be that the oral administration is compared to different parenteral
routes in the various studies. Intravenous administration provides 100% availability of the
dose, while the intramuscular route may deviate from the assumed 100%. Another possible
explanation is that different parameters have been used to calculate bioavailability. The
most reliable method is to calculate the bioavailability from blood sample data (plasma
concentrations). However, some studies base their calculations on subjective reports from
the patients (Beaver et al., I978a) or dose requirements (oral contra parenteral
administration) (Kalso and Vaino, 1990). It is unlikely that studies using different
parameters will give the same results in the calculation of oral bioavailability.
In summary it can be concluded that the bioavailability of oxycodone is markedly higher
than that of morphine. Glucuronidation at C-3 in morphine is important in its first-pass
metabolism. It has been suggested that the higher bioavailability for oxycodone is due to
methylation at C-3 (Figure 2), a feattxe that may prevent the molecule from extensive f,rrst-
pass metabolism (Beaver et al., 1978a).
1.3.4.2 Protein bindíng snd volume of dìstributíon
Leow et al. (1993) studied the serum protein binding of oxycodone and morphine in human
plasma using ultrafiltration. They found that albumin was the major binding protein for
both drugs, and that the binding was dependent on protein concentration. Moreover they
found that the affinity for AAG (ol-acid glycoprotein), an acute phase reactant protein,
was higher than for albumin for both drugs. However, the concentration of AAG in serum
of a healtþ person is much lower than albumin. The binding percentages of oxycodone to
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albumin and AAG were calculated to be 31-39 Yo and 5-10 yo, respectively. The total
serum protein binding for oxycodone in this study was 45.1+0.4o/o at physiological pH and
temperature. The drug concentration at therapeutic range (5 - 100 nglml) did not influence
the protein binding signihcantly. A decrease in albumin concentration is seen in patients
with renal and hepatic failure, while the AAG concentration will be elevated after trauma,
surgery and certain disease states. In both cases, an alteration in protein binding of
oxycodone would be expected, since the protein binding of oxycodone is dependent on the
protein concentration in plasma. Temperature and pH changes appear to have a
considerable effect on the serum protein binding. An increase in protein binding could be
detected after decreasing the temperature, while lowering the pH resulted in a signif,rcantly
reduced serum protein binding. The pharmacological action of a drug is related to the
unbound fraction of the drug in plasma. However, since the protein binding of oxycodone
is considered relatively low (<50o/o), notable alterations in the pharmacological effects of
oxycodone and its pharmacokinetics are not expected in spite of alterations in the degree of
protein binding.
Pöyhiä et al. (1991) studied the pharmacokinetics of intravenously administered oxycodone
(0.07mglkg) in post-operative patients (n:9). Volume of distribution at steady state was
2.6+0.5 L/kg (meantsD). Similarly, Leow et al. (I992b) found the volume of distribution
of oxycodone (0.08mg/kg) at steady state to be 2.5t0.8 L/kg after intravenous
administration to post-operative patients (n:48). These studies indicate that oxycodone is
highly distributed into tissues. This is also the case for morphine that has a volume of
distribution between 1 and 6Llkg in various studies and a protein binding similar to
oxycodone (Glare and Walsh, 1991).
1.3.4.3 Cleørønce ønd eliminatíon
The elimination of oxycodone is mainly hepatic (Tallgren et aI., 1997). Only 8-14%o of a
single dose is excreted unchanged by the kidneys during the flrrst 24 hours
(Pöyhiä et al., 1992). The plasma clearance of oxycodone was found to be 0.7810 .33 Llmin
in post-operative patients (n:9), which is in accordance with findings in cancer patients
(n:12) where the plasma clearance was found to be 0.81+0.44Llmin (Pöyhiä et al., 7991;
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Leow et al.1992a). The clearance of oxycodone is lower than morphine, which has a
clearance of L2-2.)Llmin (Milne et a1.,1996). The renal clearances for oxycodone and
morphine ate 0.08 and 0.10 Llmin, respectively (Pöyhiä et a1.,1992;
Glare and Walsh, 1991).
There are several studies that have estimated the halÊlife of oxycodone. Pöyhiä et al.
(1992) found the half-life after intramuscular injection of oxycodone in nine healthy
volunteers to be 4.8910.77 (meatÈSD) hours, while the halflife after oral administration in
the same subject group \¡/as 5.12+I.65 hours. Leow et aI. (1992b) studied the
pharmacokinetics of oxycodone in post-operative patients (rl2 in each group) and found
the half-life to be 5.45+1.43 hours after intravenous injection, while for IR (immediate-
release)-tablets and rectal suppositories it was 5.6511.13 and 5.40+1.19 hours, respectively.
The pharmacokinetics of oxycodone in cancer patients was investigated in another study by
Leow et al. (1992a). The mean intravenous half-life was 3.0111.37 hours, while the mean
oral half-life was 3.51t1.43 hours. Substantial inter-individual variation is seen in all the
studies. The halflife also seems to vary slightly between the different administration forms
after a single dose, and between healtþ subjects, cancer patients and post-operative
patients. These variations may be caused by differences in distribution and clearance rates,
which are altered by disease, surgery and general anaesthesia (Leow et al., 1992a). In
general, dosing is required every 4 hours when oxycodone is administered as IR-tablets,
rectal suppositories or intravenous injections. (Leow etal.,l992a; Pöyhiä etal.,l99l;
Pöyhiä et al., 1992). Table 3a summarizes the studies described above. The half-life of
controlled-release (CR) oxycodone is similar to that in immediate release oral formulations,
but dosing every 12 hours provides adequate pain control since delayed and higher C'',u*
(due to larger dose magnitude) sustain the plasma concentration within the therapeutic
range longer (Benziger et al., t997; Hagen and Babul, 1997; Citron et al., 1998;Kaplan et
al., 1998; Bruera et al., 1998).
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Table 3a Summary of studies that determine the halfJlfe of oxycodone.
Intravenous Intramuscular Oral (IR)
Healtþ voluntaries (n:9)


















1.3.4.4 Metøbolism of oxycodone
Oxycodone has several metabolic pathways, although these have not been well described in










Figure 4 The metabolism of oxycodone
A quantitatively important metabolite of oxycodone is noroxycodone (NOC).
Noroxycodone is formed by N-demethylation of oxycodone, and it is important in the first-
pass metabolism of oxycodone (Ishida etal.,1979; Ishida etal.,I982; Pöihiä etal.,1992;
Pöihiä et al., 1993). Maximum plasma concentrations after a single oral controlled-release
dose of oxycodone (20 mg) were found to be 15.'tt4.5 nglml (Kaiko et al., 1996).
Noroxycodone is considered unimportant for the analgesic effect of oxycodone. The
antinociceptive potency in rats has been shown to be 0.17 for noroxycodone relative to
morphine, while the potency of oxycodone relative to morphine was 0.44 (Leow and
Smith, 1994). This indicates that the potency of noroxycodone is less than that of
oxycodone itself, and it is therefore unlikely to contribute to the effects of oxycodone.
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Another metabolite of great interest is oxymorphone (OM), formed by Odemethylation of
oxycodone (Ishida etal,l979; Ishida etal.,l982; Pöihiä eta1..,1993). The amount of
oxymorphone formed is small compared to that of noroxycodone. Kaiko et al. (1996) found
a maximum plasma concentration of 0.82+0.85 nglml when 20 mg controlled-release
oxycodone was administered to healtþ volunteers. In other studies, the amount of
oxymorphone formed was below the limit of quantification
(Pöihiä etal.,l99l;Pöihiä etal.,1992). Even though the plasma concentration of
oxymorphone is low after administration of oxycodone, its presence is considered
important. Oxymorphone has high antinociceptive activity and may therefore contribute to
oxycodone's analgesic effect. This possible contribution will be discussed in depth in
section 1.3.5.
Oxycodone also undergoes N-oxidation and Gketo-reduction, and finally conjugation of
both oxycodone and the metabolites (Ishida etal.,1979; Pöihiä etal,1993). These
pathways are very poorly described in the literature. Pöihiä et al. (1992) found that
noroxycodone is mainly excreted as the unconjugated metabolite, while oxymorphone was
found mostly as the conjugated form in the urine. The total dose of oxycodone has not been
recovered after administration in humans. Studies in other mammalian species indicate
significant interspecies differences in urinary and faecal recovery of oxycodone and its
metabolites (Ishida et al., 1982), and conclusions on human metabolism and excretion can
therefore not be made on the basis of these studies.
1.3.4.5 Enzymes ìnvolved in the hepatíc metabolísm of oxycodone
The enzymes involved in the oxidative metabolism of oxycodone in humans are poorly
described. CYP2D6 is involved in the Odemethylation of codeine, dihydrocodeine and
hydrocodone, drugs that are structurally similar to oxycodone (Mortimer et a1.,1990;
Kirkwood et al.,l997b; Hutchinson, 1999). Several studies suggest that CYP2D6 also is of
major importance in the formation of oxymorphone from oxycodone (Otton et al., 1993;
Heiskanen et a1., 1998; Brauer and Ralfkiær, 1998). However, it is not clear whether the O-




Otton et al. (1993) used specific and non-specific CYP2D6 inhibitors to investigate the
enzyme involvement in the O-demethylation of oxycodone in human liver microsomes.
Quinidine, a CYP2D6 specihc inhibitor, inhibited the forrnation of oxymorphone in a
concentration-dependent manner when oxycodone was incubated in microsomes from a
CYP2D6 EM liver. Fluoxetine, which is a nor¡selective inhibitor of CYP2D6, showed
similar inhibitory effect to quinidine in the same liver. Formation of oxymorphone was also
evident in microsomes from a CYP2D6 PM, but the formation was five fold lower than that
of the EM. Quinidine had no inhibitory effect on the formation of oxymorphone in this
liver. However, they found that fluoxetine inhibited oxymorphone formation in the same
PM liver in a similar manner to that seen for the EM. This study showed that CYP2D6 is
involved in the O-demetþlation of oxycodone. The presence of OM in the PM and the
lack of inhibition by quinidine in the PM indicates that enzymes other than CYP2D6 arc
involved in the formation of oxymorphone in addition to CYP2D6. This activity is
inhibited by fluoxetine. Support from studies in other PM livers is needed, since there are
intra-phenotype differences in metabolic activity.
Heiskanen et al. (1998) conducted a double-blind crossover study where the plasma
oxymorphone concentration was measured over time after administration of 20mg CR-
oxycodone with quinidine (200mg) or placebo premedication. Ten healthy volunteers were
included in the study, and all the subjects v/ere EM with respect to CYP2D6. Quinidine
effectively blocked the formation of oxymorphone, and since the concentration of
oxymorphone was unmeasurable in 8 of 10 subjects after quinidine premedication it was
concluded that CYP2D6 is the only enz)¡me involved in oxymorphone formation. The
validity of the conclusion can be questioned since only a few values in the presented
plasma oxymorphone concentration curve for the placebo group were above the limit of
quantification (0.2 nglml).
Noroxycodone formation may be dependent on CYP3 A4; an assumption made on the basis
of studies conducted on structurally similar phenanthrenes. N-demethylation of codeine,
dihydrocodeine and hydrocodone aÍe dependent on CYP3A4 (Mortimeretal.,l990;
Kirkwood et al.,1997b; Hutchinson, 1999). Brauer and Ralfkiær (1998) also indicated this
involvement in preliminary studies on oxycodone.
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1.3.5 The analgesic potency oÍoxycodone
Since the analgesic effect of opioids has traditionally been related to the degree of p-
receptor binding, oxycodone should be less potent than morphine (section 1.3.3.1).
However, the analgesic potency of oxycodone has been shown to be the same as for
morphine in the treatment of acute postoperative pain, and 0.7 the potency in cancer pain
(Kalso et al.,l99l; Beaver et al., 1978b). The suggested explanations for this have forked
into two main theories. The f,rrst theory involves other receptors as responsible for
oxycodone's analgesic effect (Ross and Smith, 1997), while the second, and the most
supported theory, suggests that oxycodone acts as a prodrug (Cleary et al., 1994).
It has been suggested that oxycodone has an intrinsic antinociceptive effect, and that this is
mediated by CNS r-receptors. Ross and Smith (1991) supported this theory with studies in
rats, which have been fully described in section I.3.3.2. A recent study showed that co
administration of sub-analgesic doses of oxycodone and morphine in rats resulted in
marked antinociceptive synergy, and that adverse behavioural effects (e.g. sedation) were
reduced compared to equipotent doses of either opioid alone (Ross et al., 2000). Pre-
administration of the r-receptor antagonist nor-binaltorphimine reduced the synergistic
antinociceptive effect of oxycodone (4Onmol) and morphine (15nmol)
(intracerebroventricular dosing) to a level equivalent to that of morphine (l5nmol) alone
(no more than 20o/o of the maximum possible effect). No antinociception was found for
oxycodone alone at 4Onmol, and pre-administration of the p-receptor antagonist
naloxonazine completely abolished the synergistic antinociception of morphine and
oxycodone. These data further support the involvement of r-receptors in oxycodone
nociception. However, no studies have investigated r-receptor involvement in oxycodone
analgesia in humans.
When a drug elicits its effect through its metabolite(s) it is referred to as a prodrug. A low
receptor affinity of the original drug molecule may therefore not indicate the magnitude of
the drug's effects in vivo.
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Codeine, an opioid recommended for mild to moderate pain, has been used as an example
of a prodrug. Codeine has a very low affinity (Ki:248nM) for the p-receptor, but still
induces analgesic effect in most subjects (Chen etal.,l997a; Chen etal.,l99lb; Sindrup
and Brøsen, 1995). It has been shown that about l0 o/o of the administered codeine is
metabolised into morphine by O-demethylation, and that morphine has a high ¡r-receptor
affinity (Ki:l.2nM) (Adler et al., 1955; Chenetal., 1991a). Therefore it was originally
believed that the analgesic effect of codeine is due to formation of morphine. Lack of
morphine formation from codeine in subjects that are poor metabolizers with respect to
CYP2D6 shows that O-demethylation of codeine is dependent on CYP2D6 (Mortimer et
a1.,1990; Chen et al., 1991b). Studies in humans have revealed that codeine has no effect
on experimental pain in CYP2D6 PMs and CYP2D6 EMs pre-treated with quinidine
(CYP2D6 inhibitor) (Sindrup et al., 1990; Caraco et al., 1996a; Sindrup et al., 1992), thus
supporting the theory of codeine as a prodrug with morphine as the active metabolite.
Oxycodone is closely related to codeine in chemical structure, and oxymorphone has the















A similar relationship to that of codeine and morphine has, as a result of the structural
resemblance, been suggested for oxycodone and its O-demetþlated metabolite
oxymorphone (Cleary et a1.,I994). This could be the explanation for the substantial
analgesic potency of oxycodone.
The concentration of oxl.rnorphone in plasma after administration of oxycodone is low, but
oxymorphone has a p-receptor affinity 20 times that of morphine and 60 times that of
oxycodone (Beaver etal.,l9l7; Chenetal., 1991a). Oxymorphone might therefore be
responsible for the analgesic effect despite the small amount formed.
Several studies in animals and humans have aimed to evaluate the role of oxymorphone in
mediating the opioid effects of oxycodone, and some of these studies are described below.
Cleary et al. (1994) studied the analgesic effect of oxycodone and codeine in a rutin vivo
model. Female Dark Agouti (DA) rats, which lack the CYP2DI eîryme (the rat's analogue
to human CYP2D6), represented the PM, while the Sprague-Dawley (SD) rats having the
eîzyme present, represented the EM. The analgesic effect of oxycodone and codeine was
measured by the "tail-flick-latency-time test". DA rats, and SD rats injected with quinine, a
specific inhibitor of CYP2Dl, had the same maximum response to oxycodone as SD rats
(without quinine), but the effect was prolonged. This indicated that oxycodone itself, rather
than oxymorphone, is responsible for the effect of oxycodone. In contrast, codeine proved
to be a prodrug dependent on the CYP2Dl pathway since the DA and quinine treated SD
rats had a signif,rcantly reduced analgesic effect compared to the SD rats (untreated). It was
implied that even very low oxymorphone formation could have been enough to produce an
analgesic effect after oxycodone treatment due to the high p-receptor affinity of
oxymorphone, but this does not explain the prolonged action of oxycodone in the CYP2Dl
impaired rats.
Heiskanen et al. (1998) concluded that the drug effect of oxycodone is probably not
mediated by oxymorphone, since pre-administration of the CYP2D6 inhibitor (quinidine)
in 10 healthy CYP2D6 EMs did not change drug effects as measured by subjective
symptoms, psychomotor function and specif,rc drug effect questionnaire ratings. Howevet,
this study only assessed drug effects other than analgesia, and since pain was not present in
the subjects the study does not explain the high analgesic potency of oxycodone.
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Maddocks et al. (1996) studied the extent of delirium in oxycodone and morphine in 13
cancer patients. It was found that the only CYP2D6 PM in the study did not achieve
adequate pain-control after administration of oxycodone (Table 3), and the patient also
needed higher breakthrough doses. This indicated that a CYP2D6 dependent pathway is
responsible for the analgesic effect of oxycodone. Studies in more patients are needed to
decide whether the phenotype of the patient was the reason for lack of analgesic effect.
Only one PM was included in the study, and substantial inter-individual variability was
seen amongst the EMs.
Table 3b Visual Analogue Scale scores for pain in CYP2D6 EMs and PM (Maddocks et al., 1996).
Studies in rats showed that the concentration of morphine in the brain was significantly
higher than in plasma after administration of codeine (Chen et al., 1990). Similarly, it has
been shown in humans that morphine concentration in cerebrospinal fluid is higher than in
plasma after codeine intake (Sindrup et al., 1996). This may be due to Odemetþlation of
codeine in the brain, in close relation to opioid receptors, and it has therefore been
suggested that the plasma concentration of morphine after codeine administration may be
irrelevant for the analgesic effect of codeine (Chen et al., 1990; Sindrup and Brøsen,1995;
Sindrup et a1., 1996). Similar studies with oxycodone have not been published.
In conclusion, the reason for the high analgesic potency of oxycodone in humans is yet not
known, and disagreements are seen in the current research.
1.3.6 Summary
Oxycodone appears to have several clinical advantages compared to other similar opioids
(e.g. morphine), such as diminished side effects and a high oral bioavailability. Alternatives
are needed when selecting analgesics in the treatment of pain, and the advantages provided
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The metabolism of oxycodone is poorly described, and the involvement of different P450
isoforms has not yet been systematically tested. This is an area of great interest since
pharmacokinetic and pharmacodynamic properties of drugs are altered due to modulation
of enzyme activity. First, the influence of genetically or environmentally determined
differences in expression of various cytochrome P450 enzymes on oxycodone cannot be
predicted without knowledge of which enzymes are involved in oxycodone metabolism.
Second, knowledge of en4rme involvement is also needed in order to prevent interactions
with other drugs metabolised by the same enzyme(s). And finally, further knowledge about
enzyme involvement in oxycodone metabolism may benefit future research on the
importance of oxymorphone in mediating oxycodone analgesia.
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7.4 Scope of present reseørch
1.4.1 llypotheses
The following hypotheses \À/ere made on the basis of preliminary research on oxycodone
and results from research on drugs of similar structure:
CYP2D6 is the major CYP enzyme involved in the oxidative metabolism ofoxycodone
to oxymorphone
CYP3A4 is the major CYP enzyme involved in the oxidative metabolism of oxycodone
to noroxycodone
1.4.2 Aims
The aims of the research described in this thesis were:
to investigate the enz5rme kinetics for the formation of noroxycodone and oxymorphone
from oxycodone in human liver microsomes
to identify which liver P450 isoenzyme(s) are involved in these two metabolic reactions
Human liver microsomes from 6 CYP2D6 EMs and I CYP2D6 PM were used to study the
oxidative metabolism of oxycodone. Formation of oxymorphone and noroxycodone was
measured using high performance liquid chromatography (HPLC). Kinetic data were
obtained by frtting the Michaelis Menten equation to the metabolite(s) formation data.
Chemical inhibitors, antibody inhibitors and expressed enzymes were used when
investigating the involvement of specif,rc liver P450 enzymes.
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2. Materials ønd Methods
2.1 Chemicøls
Noroxycodone and ox¡rmorphone hydrochloride were obtained from Du Pont
Pharmaceuticals, (V/ilmington, Delaware, USA). Oxycodone hydrochloride, bovine serum
albumin - fraction V (BSA), folin-ciocalteau reagent, diethyldithiocarbamate (DDC), DL-
isocitric acid Na¡, isocitrate dehydrogenase (NADP, type IV), sulphaphenazole,
troleandomycin (TOA), coumarin, chlorzoxazoîe, hydromorphone hydrochloride and
sodium perchlorate (NaClOa) were purchased from Sigma Chemical Company (St Louis,
Missouri, USA). Furafylline and S-mephenytoin were purchased from Ultrafine Chemicals
(Manchester, England). Ketoconazole was purchased from Janssen Pharmaceuticals
(Beerse, Belgium). Dextromethorphan was obtained from Roche Products Pty Ltd (Sydney,
New South Wales, Australia). Quinidine sulfate and NADP-Na2 were purchased from
Merck (Darmstadt, Germany). Sodium carbonate (NazCO:) and potassium di-hydrogen
orthophosphate (KH2POa) were obtained from Merck Pty Ltd (Kilsyth, Victoria, Australia).
Copper sulfate (CuSOa), dimetþl sulfoxide (DMSO), magnesium chloride (MgCl2), di-
sodium hydrogen orthophosphate (Na2HPOa), potassium chloride (KCl), sodium hydroxide
(NaOH), potassium-sodium tafirate (K*-Naltartrate), orthophosphoric acid and
hydrochloric acid (HCl) were obtained from Ajax Chemicals (Sydney, New South Wales,
Australia). Acetonitrile (ACN), dichloromethane (DCM) and methanol came from BDH
Laboratory Supplies (Poole, England). Etþlenediaminetetra-acetic acid (EDTA) was
obtained from BDH Chemicals Australia (Kilsyth, Victoria, Australia). Carbon monoxide
(CO) was obtained from CGI (Adelaide, South Australia, Australia). Sodium dithionate
was obtained from May & Baker Ltd. (Dagenham, England). MilliQ water was used in all
experiments.
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2.2 Humøn liver mícrosomes
2.2.1 Liver tissue
Samples of livers had been collected from patients with hepatic tumors who underwent
liver resection at the Royal Adelaide Hospital. Ethical approval had been obtained from the
Research Ethics Committees of the Royal Adelaide Hospital and the University of
Adelaide, and the patients had given their written informed consent for the liver tissue to be
studied. Clinical details, demographic data and CYP2D6 genotype/phenotype are tabulated
in Appendix A.
Seven livers were used in this project (internal numbers: #5, #ll, #21, #23, #24, #31 and
#35). Samples from the livers used were CYP}CL9 genotyped (tested for CYP2CI9*2 and
CYP2CI9*3 alleles) in this laboratory using polymerase chain reaction (PCR) (Coller et al.,
7997), while CYP2D6 genotype had been deterrnined (tested for CYP2D6*3 and
CYP2D6*4A/B alleles) for all the livers by the Institute of Medical and Veterinary Science
(Adelaide, Australia) according to an established PCR method (Heim and Meyer, 1990).
2.2. 2 Preparation method
Human liver microsomes \¡/ere prepared after the method described by Zanger et al. (1988).
In order to maintain the enrymatic activity, the liver samples had been stored at -80oC, and
all preparation steps were carried out at 4oC. Storage on ice was used at all times, and the
preparations were always transported on ice.
Frozen liver was cut into small pieces and preparation buffer (lmM EDTA and 0.15M KCl,
pH adjusted to 7.3) was added. A mechanical homogenizq (Ulha Turax, Staufen i.
Breisgau, Germany) was used to homogenize the liverþreparation buffer mix, and a
uniform suspension was obtained after approximately 15 seconds. The suspension was
filtered through gaùze, and the flrltrate was transferred to tubes f,rtting the rotor head of the
centrifuge (Beckman J2-21, Beckman Instruments, Inc., Palo Alto, California, USA). After
15 minutes of centrifugation at 12 000 g, a pellet of waste (membranes etc.) was formed at
41
Materials and Methods Chapter 2
the bottom of the tube, and fat Iayer was floating on the top of the supernatant. The
supernatant (without the fat) was transferred to new tubes, and centrifuged again for 15
minutes at 27 000 g (Beckman J2-21). The supernatant of this was carefully transferred to
tubes made for the ultracentrifuge (Beckman L7-55, Beckman Instruments, Inc.), and
centrifuged for 60 minutes at 105 000 g. This centrifugation splits the cytosol from the
membranous parts of the cell, leaving the latter as a pellet at the bottom of the tubes. The
pellets were resuspended in wash buffer (0.1M phosphate buffer with 1.0 mM EDTA,
adjusted to pH 7.25), and recentrifuged at 105 000 g for 60 minutes. The resulting
microsomal pellet was resuspended in storage solution (0.1M phosphate buffer with 1.0
mM EDTA, adjusted to pH 7.4). Approximately 1 ml storage solution per 2 grams original
tissue weight was used. The microsomes were stored in aliquots of 0.5 ml at -80oC and
thawed only once prior to use.
2.2.3 Determinøtion of protein concentration
The protein concentration of the microsomal suspensions was determined after the method
described by Lowry et al. (1951).
Six standards of bovine serum albumin (BSA) were prepared in duplicate over a protein
concentration range of 0 to 800 pg/rnl. The microsome samples \Mere also prepared in
duplicate at ll25 and 1/50 dilutions. The unknown samples and standards were treated the
same as follows:
Two milliliters of Solution A (0.5m1 2o/o CxSO¿,, 0.5m1 4% K+-Na+-tartrate, 49ml 3o/o
Na2CO3/0.4% NaOH) were added. The tubes were vortexed and placed on icc for 10
minutes. Two hundred microlitres of Solution B (3ml millipore water, 1.5m1 folin
ciocalteau reagent) were added and the samples were then placed on ice in the dark for
another 30 minutes. The ultraviolet absorbance of the standards and unknown samples was
read at 550nm using a variable wavelength spectrophotometer (Hitachi U-2000, Hitachi
Ltd, Tokyo, Japan). The protein concentration of the unknown samples was determined
from the standard curve formed from the BSA samples.
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2.2.4 Determínution of cytochrome P450 content
The cytochrome P450 contents of the microsomal samples were determined after the
method of Omwa and Sato (1964).
Microsomal suspensions were diluted 1 in 7.5 with 0.1M potassium buffer (pH:7.4), and
then bubbled with carbon monoxide at a rate of I bubble/second for 30 seconds. Each
sample was divided in two cuvettes, and a background scan from 400 to 500nm was
performed by the use of a double beam spectrophotometer (Hitachi, model U-2000, Hitachi
Ltd., Tokyo, Japan). A few crystals (1-2mg) of fresh sodium dithionite were added to one
of the cuvettes. The cuvette was inverted gently to mix before it was replaced in the
spectrophotometer and scanned at wavelengths from 400-500nm. Cytochrome P450
content was calculated by using the following formula:
Total. CYP450. content =
(Aoro - Aon)after.Na o - Aonn)baseline
0.106
(0.106 = molar extinction coefficient for CYP450, A: absorption)
Correction was made for dilution and measured protein concentration (2.2.3) b achieve a
final value in nmol CYP450/mg protein.
(
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2.3 Oxycodone metabolísm studíes
2.3. 1 Method development
The incubation method used in this study was developed in preliminary studies by Brauer
and Ralfkiær (1998). They tested an incubation procedure for oxycodone in human liver
microsomes, and a method for extracting oxycodone and its metabolites from the
incubation mixture. The methods are similar to previous studies on oxycodone by Otton et
al. (1993) and Cleary et al. in this laboratory (unpublished). Kirkwood et al. (1997a) and
Foster et al. (1999) also used similar methods for the incubation of dihydrocodeine and
methadone in human liver microsomes.
2.3.2 General procedures for microsome incubøtíon
The total volume of the incubations was generally 250p1, except in some of the high
substrate concentration samples for the kinetic studies. The incubations were carried out in
1Oml flat bottom plastic tubes.
The microsomes were diluted in storage buffer (lmM EDTA, 0.lM NaHPOa, pH:7.4) to a
protein concentration of 2.5 mgln1, (50¡rl in incubation mixture -+ 0.5 mg/ml). This had
been determined in a protein-dependency study (section2.7.L).
Oxycodone was diluted in incubation buffer (0.lM Na2HPO4 pH:7.4) since the enzymatic
activity of the microsomes proved to be pH-sensitive in preliminary studies (section 2.7 .3).
NADPH regenerating system was made up from isocitrate dehydrogenase (1 mglml),
NADP-Nat* ltOmtr,t¡, Dl-isocitric acid-Na3 (50mM) and MgCl6x6HzO (50mM). MilliQ
water was used to dissolve the components. The solution was stored at -20C in aliquots.
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2. 3. 2. 1 Terminøting metøbolite formøtion
An alkaline solution (20%o Na2CO3) was used to stop the reaction. Alkalinisatlon causes
oxidation of the opioid amine moiety, a reaction that is necessary for the opioiô to extract
into the organic solvent (dichloromethane) (Kirkwood et al, 1997a). Brauer and Ralfkiær
(1998) tested the eff,rciency of 20% N4CO: in stopping the metabolite formation from
oxycodone in human liver microsomes and found that no difference was seen in metabolite
formation after the samples had been left for 10 and 30 minutes on ice.
2.3.2.2 Internal støndard
Hydromorphone hydrochloride had been selected as the internal standard in preliminary
studies by Brauer and Ralfkiær (1998). It did not interfere with any of the peaks, and the
recovery was similar to oxl.rnorphone and noroxycodone in the selected organic extraction
solvent (dichloromethane). The internal standard was made up as a 10 ¡rglml solution in
MilliQ water.
2.3.3 Kinetic studíes
13 different oxycodone concentrations \Mere incubated with the microsomes in duplicate to
deterrnine their Michaelis Menten kinetics.
The samples contained:
. 25VINADPH regenerating system
. 50pl microsome suspension (2.5 mglml protein)
' 175ltl substrate
The oxycodone concentrations used ranged between 50pM - 20000pM, which made the
corrected concentration in the incubation mixture between 35pM 14000pM.
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2. 3. 3. 1 Incubation method
175 ¡tl substrate and25¡tl NADPH regenerating system were pipetted into 10ml plastic
tubes. The reaction was started by adding 50 pl of the microsome suspension to the
tubes
The tubes were placed in shaking water bath (Julabo SW-20C, Julabo Labortechnik
GMBH, Seelbach, Germany) at 37"C for 60 minutes (based on time dependency study
- section 2.1.2). The reaction was then stopped by adding 300 pl 20% NazCO3, and the
tubes were placed on ice for ten minutes. Internal standard (70 pl) was added separately
just after the stop solution.
Exceeding the highest calibration standard for noroxycodone formation made the
noroxycodone quantification difficult in three livers. The problem was solved by repeating
these particular samples with only half the volumes of all components in the incubation
mixture. Another approach to the problem was to half the incubation time. However, the
results were better with reduced volumes due to better separation of the peaks when bss
substrate was present.
2. 3.3.2 Extractíon method
4ml dichloromethane were added to each tube. The tubes were rotary mixed for 5
minutes and then centrifuged at 17009 for 5 minutes
The aqueous upper layer was removed, since the drug and metabolites now had been
extracted into the organic solvent. The organic phase was transferred to new 10ml tubes
containing 200¡rl 0.1M HCl. The tubes were rotary mixed for 5 minutes and then
centrifuged at 17009 for 5 minutes.
The analytes had now been back-extracted into the acid, and 15Qrl of the acidic layer
(appearing as a bubble on top) was transferred to auto-sampler vials.
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2.3.3.3 Standards & Quølity Controls
The metabolite formation needed to be quantified for Michaelis Menten kinetic
determination. A standard curve was therefore needed, and quality controls (QC) in
duplicate were made to verify the accuracy and precision of the standard curve.
The standard/QC samples contained:
. 50pl microsome suspension (2.5 mglml protein)
' 150p1incubationbuffer
. 50pl standard/QC
These samples were incubated and extracted using the same procedure as the unknown
incubation samples, except that NADPH was excluded in order to save on this expensive
chemical. Brauer and Ralfkiær (1998) showed that omitting NADPH from the standard
incubations did not alter the slope for the oxymorphone standard curves significantly.
However, a statistically significant alteration of the slope (-ll%) was seen for the
noroxycodone standard curve when NADPH was excluded from the incubation mixture. In
spite of this minor alteration, it had been decided to exclude NADPH since the main focus
of the project was qualitative rather than strictly quantitative, and due to the high cost of
the NADPH regenerative system. These decisions were also valid for the current project.
Preliminary studies by Brauer and Ralfkiær (1998) indicated that the forrnation ratio
between ox5imorphone and noroxycodone is approximately 1:10. From this it could be
concluded that the oxymorphone concentration in standards and QCs had to be about 10
times lower than the noroxycodone concentration.
Stock solutions of oxymorphone and noroxycodone for the standards were made up by
diluting the hydrochloride salt of oxynorphone in water and the free base of noroxycodone
in methanol, to concentrations of 2 mM and 3 mM respectively. The standards were
prepared from the fresh stock solutions in a concentration range from 0.334- 50 pM for
oxymorphone and 5 - 500 FM for noroxycodone. Since the standards were diluted by one
in fîve in the incubation mixture, the final concentration ranges were 0.134- 10 ¡rM for
oxyrnorphone and 1 - 100 ¡rM for noroxycodone, and the assays comprised 8 standard
samples. Another higher standard was later added due to excessive formation of
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noroxycodone for some livers. This standard was made by doubling the volume of the top
standard in the incubation mixture (keeping the total volume the same), and the frnal
concentrations of metabolites were 20¡rM for oxymorphone and 20qrM for noroxycodone.
Quality controls (QCs) were made up from stock solutions prepared in 1998 by PhD
student David Foster. These dilutions had been made up from individual weightings, and





Table 4 Quality controls (QC) used with calibration curve: concentration of QC in incubation mixture
(HQC:high quality control, MQC:middle quality control, LQC: low quality control)
An analytical run comprised 8-9 standards, 6 QCs (duplicates of HQC, MQC, LQC), and
the unknown samples.
2. 3.4 Chemicøl inhibitor experiments
Chemical inhibitors with known CYP specif,rcity were incubated concomitantly with
oxycodone in microsomes from three extensive metabolizer livers (HLM#I l, #31 and #35)
and one poor metabolizer liver (HLM#24) to investigate which CYP isoenzymes are
involved in the metabolism of oxycodone. The inhibitors were tested at a fixed oxycodone
concentration that had to be in the vicinity of K¡a for each of the two metabolic pathways.
The rate of formation is linear up to the Krr¡ substrate concentration, and the detection of
inhibition or induction will therefore be more accurate. Since NOC and OM formation had
highly different K¡a values, the experiments had to be carried out twice for each liver. OM
and NOC formation were compared to the formation in control samples containing the
same solvent concentration as that in the inhibitor samples. All incubations were carried

























































Table 5 Chemical inhibitors used in the characterisation of CYP450 isoforms involved in OC
metabolism. The solvents used to dilute the inhibitors are listed in the right column.
The inhibitors were incubated without OC to determine if the inhibitors themselves or
possible metabolites were extracted, and whether they caused any interfering HPLC peaks.
DDC and quinidine each had a late eluting peak at about 180 minutes, which made it
necessary to have longer HPLC run time for these samples. One inhibitor (omeprazole) had
to be excluded due to multiple interfering peaks.
The incubation mixture for the inhibitor studies contained:
' 125þl substrate
' 25pl NADPH
. 50pl inhibitor or 50¡rl solvent to substitute the inhibitor
. 50pl microsome suspension
The procedures for incubation and extraction were the same as for the kinetic studies,
except that furafylline, TOA and DDC had to be preincubated with the microsomes in the
presence of NADPH for 15 minutes due to their mechanism of action. These three
inhibitors inactivate the enzymes only if they can complex with the isoenzyme in the
presence of NADPH (Newton et al., 1995). In these samples the reaction was started with
the addition of substrate.
Hickman et al. (1998) and Chauret et al. (1998) have shown that different solvents that are
commonly used to dissolve chemical inhibitors can affect CYP mediated metabolic
reactions. The control samples were therefore compared to a duplicate that only had
incubation buffer in addition to substrate, NADPH and microsomes.
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2.3.5 Antibody ínhíbitíon stadíes
Microsomes from three extensive metabolizer livers (HLM#21, #31 and #35) were used to
examine the inhibition by monoclonal antibodies on oxycodone metabolism. Monoclonal
antibodies to CYP2D6, CYP3A4, CYPIA2 and CYP2EI (selected on the basis of the
chemical inhibitor studies) were obtained from GENTEST Corporation (Massachusetts,
USA), and stored at -20"C as recommended by the manufacturer. The protein content of
the monoclonal antibodies was lOmg/ml, and the amount used in the incubations ranged
from 2.4-8p1/100¡rg microsomal protein. This was in accordance with the manufacturer's
recommendations.
LKM1 (liver/kidney microsomal antibody fype 1) positive serum was also examined in all
three livers. The main autoantigen for LKM1 is CYP2D6 (Manns et a1.,1989), and the
serum can therefore be used in inhibitory studies to investigate CYP2D6 involvement in
metabolic reactions. The serum was obtained from a patient suffering from autoinünune
chronic hepatitis, and the antibody titre in the serum was 64. The amount of serum used in
the incubations ranged from 0.2-2¡tll5 Opg micro somal protein.
Oxycodone was incubated at a concentration near the oxymorphone Kv value for
formation of the respective liver sample. Oxymorphone and noroxycodone formation were
compared to that of a control containing the antibody solvent (Tris buffer for the
monoclonal antibodies and control serum from a healtþ volunteer for the LKM1
antibodies). All incubations were carried out in duplicate.
2.3.5.1 Incubation procedure for the sntibodies
The samples were prepared in Eppendorf tubes due to the small volumes used at the initial
stages of the procedure.
. The antibodies were pre-incubated with 50pl microsomes on ice for l0minutes
. 25pl NADPH regenerating system and necessary incubation buffer were added (total
volume of incubation mixture after addition of substrate was 250¡rl)
. The reaction was started with the addition of 125¡rl oxycodone (samples shaken softly
by hand), and incubation time was as usual 60 minutes
. The reaction was stopped with 300p1 20o/, NazCO3, and 60¡rl internal standard was
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added before the tubes were vortexed and placed on ice for 10 minutes
. The total volume of the samples was then transferred to 10ml tubes
The extraction procedure was the same as for the kinetic studies (section 2.3.3.2).
2.3.6 Expressed CYP enzymes
Microsomes from human lymphoblastoid cells containing CYP2D6 and CYP3 A4, and
insect cell supersomes containing CYP2D6, CYP1 A2 and CYP}CI9 were obtained from
GENTEST Corporation (Massachusetts, USA). The enzymes were stored at -80'C
according to the manufacturer's recommendations. The enzymes were incubated with
oxycodone in duplicate and screened for oxymorphone and noroxycodone formation. Since
oxymorphone and noroxycodone formation have different K¡a values, the substrate
concentration was fixed between the two K¡a concentrations at 100qJM. It was decided to
keep the amount of CYP450 in the incubation at a constant level (6pmol P450/incubation),
although this involved a slight variation in the protein concentrations between the enzyrnes.
This assay was run with a calibration curve and quality controls in order to quantify the
metabolite formation.
2.3.6.1 Incubøtíon procedure for the expressed enTymes
. The expressed enzymes were thawed quickly and kept on ice until use
. I25Wl oxycodone, 25¡tI NADPH regenerating system and incubation buffer (at a
volume that would make the final volume of incubation mixture 250p1) were pipetted
into Eppendorf tubes and pre-warmed in a shaking water bath for ten minutes
. The reaction was started with the addition of expressed enzymæ (samples shaken softly
by hand)
The rest of the procedure was the same as previously described in the antibody inhibitor
studies (section 2.3.5.1).
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2.3.6.2 Kinetic studìes ín expressed en4ymes
Kinetic studies of the metabolites formation by CYP3A4 and CYP2D6 lymphoblastoid
microsomes and CYP2CI9 supersomes were conducted for the purpose of comparing the
K¡4 values for the expressed enz)¿mes with those obtained in the human microsome kinetic
studies. The microsomes and supersomes were incubated with varying concentrations of
oxycodone (35-525pM for CYP2D6, 525-7000pM for CYP3A4 and CYP2C19), and the
protocol was followed as above (section 2.3.2 and2.3.3).
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2.4 Hìgh Performønce Líquíd Chromatogrøphy (HPLC)
assøy Íor noroxycodone und oxymorphone in microsomes
Reversed phase HPLC was used to quantify oxymorphone and noroxycodone formation.
The HPLC method used in this study was a modification of the method used by Hutchinson
(1999) to study the oxidative metabolism of hydrocodone.
The HPLC system consisted of a ShimadzuLC-íA liquid chromatograph pump (Shimadzu
Corporation, Kyoto, Japan), a Shimadzu SIL-94 autosampler, a Shimadzu C-R6A
chromatopac integrator and a Jasco UVIDEC-IOGV UV spectrophotometer (Japan
Spectroscopic Co. Ltd., Toþo, Japan).
The stationary phase consisted of a 53.mm x 7mm Platinum EPS C18 10043U Rocket
column and 10mm ALLTIMA C18 5U precolumn (Alltech Associates, Inc, Deerfield,
Illinois, USA).
The mobile phase was composed of I o/o acetonitrile, 20 mM KH,PO¿ and 10 rnM NaClOo,
and the pH was adjusted to 3.0 with ortho phosphoric acid (10M). The mobile phase was
filtered and then degassed by sonication for at least 15 minutes.
The flow rate was 3.0 ml/min and the absorbance was measured at 210nm.
A typical HPLC chromatograph after incr¡bation of oxycodone with human liver














Figure 6 A: HPLC chromatograph from blank HLM extract. B: HPLC chromatograph from extract
only containing internal standard. C: Typical HPLC chromatograph following incubation of




















2.5.1 Assay calibration curve
Peak heights obtained from the chromatograms were used for data analysis. Peak height
ratios of metabolites to internal standard were plotted against the known metabolite
concentration of the standards in order to determine the calibration curves. The slope,
intercept and 12 of the standard curves were then calculated using linear regression analysis
(Regression, Blackwell Scientific Publications Ltd., Oxford, England) with l/y weighting.
Percent deviation of standards from line of best fit was calculated using Excel 97
spreadsheet.
2.5.2 Michaelis Menten kinetics
Oxymorphone and noroxycodone concentrations of unknown samples were calculated
from the calibration curves using Excel 97 spreadsheet. Velocity of metabolite formation
(v) was calculated as a function of metabolite formation (mol), microsomal protein content
of incubation mixture and incubation time using the same software.
Eadie-Hofstee plots (v versus v/S) were made using Cricket Graph or Prism3.02. Visual
inspection of these plots was used to assess whether to fit a one or two enzyme model for
the Michaelis Menten kinetics.
The Michaelis Menten equation (Regression) was f,rtted to the kinetic data, and values for
V',nu* and K¡a could be obtained.
One enzyme model:
Two enzyme model: "=(
X ,s
Kr, + [s]
v : velocity of metabolite formation
[S] : substrate concentration
V,.*: maximum velocity of metabolite formation
K¡a: Michaelis Menten constant (a measure of the enzyme's affinity for the drug (oxycodone))
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Weighting of the data used was not the same in all parts of the study (no weighting, lly or
lly*y weighting). The criteria used to determine the weighting is discussed under the
results of the kinetic studies (section 3.3.1 and 3.3.2).





Vur^*t , Vrrru*2=-K,, K,,
The intrinsic clearance is the liver's ability to metabolise a drug in the absence of
restricting factors (liver blood flow and plasma protein binding). Clint is directly related to
the metabolic capacity of the involved enzymes.
2.5.3 Chemical and øntìbody inhibitor studies
The formation of metabolites in the chemical inhibitor and antibody inhibitor assays was
evaluated as percent formation of the respective control samples. The percent variability
within the duplicates v/as calculated, and the data were expressed as the meanlSD of the
three livers. Statistical significance of inhibition or induction was tested using a paired, two
tailed Student t-test with significance limit set at p<0.05.
2.5.4 Expressed enzyme studies
Standard curves as described above were used in the expressed enzyme studies to quantify
the metabolite formation. The Michaelis Menten equation was used to generate kinetic
profiles and to determine the K¡a for the enzymes that showed involvement in an initial
screening study. The Kv for the individual enzymes could then be compared to that
determined in the microsome kinetic studies. All data are presented as meanlSD, and in
some cases median and range. Percent coeff,rcient of variation (%CY) was calculated by




2.6. 1 Calibration curves
In order to set the acceptance criteria for an analytical run, the method had to be validated
prior to the kinetic studies. The standard procedure in the laboratory is to run 6 separate
calibration curves with quality controls (QC- 2 each of HQC, MQC, LQC), of which one
is more extensive with 6 of each QC and 6 of the lowest standard. The latter was used to
calculate the intra-assay variability (precision and accuracy) and limit of quantification
(LOQ), while the inter-assay variability (precision and accuracy) was determined from all 6
calibration cruves. The following formulae \Mere used to calculate precision(as %CV) and





o/IACCUTACY = x 100
(mean.concentration : mean estimated concentration, nom.concentration : nominal concentration)
2.6.1.1 fntur øssay validation results
The percent coeff,rcient of variation (%CY) was well below 10 percent for the slope in all
calibration curves obtained during the validation. Percent accuracies were lower than 10
percent for of all the QC concentrations (Table 6 and 7). Figure 7 shows examples of
calibration curves for noroxycodone (NOC) and oxymorphone (OM) obtained in the assay
validation.
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0 NOC concentration (uM) 100











0 OM concent¡ation (uM) 10
Figure 7 Examples of calibration curves for NOC and OM obtained in the assay validation.
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2.6.1.2 Intrø assay validøtíon results
All QC concentrations resulted in percent accuracies within l5o/o (Table 8 and 9).























































2.6.1.3 Limit of quantificútion (LOQ)
The limit of quantification (LOQ), def,rned as the lowest standard for each metabolite,
showed an inaccuracy of 15.5 and 14.6 % for NOC and 11.8 and 18.5% for OM in the
inter-assay and intra-assay validation. The precision was less than l0o/o for both analytes
(Table 10 and 11).
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2.6.1.4 Assay acceptønce cr¡teria
The assay acceptance criteria were set as a result of the validation, and were in accordance
with the standard procedures for the laboratory. To be accepted the calibration curves
should have:
r Less than 10 % deviation from line of best fit for standards with exception of the lower
two which should be respectively less than 15 %o and 20 %. At least 7 of the standards
have to be within these criteria.
r Less than 10 % deviation from nominal concentration for HQC and MQC. Less than
20o/o deviation for LQC. One of each QC has to meet these criteria, and a minimum of
4 QCs in total have to be valid.
. f>0.99
2.6.2 Recovery study
A recovery study was carried out as part of one extensive calibration curve in the validation
study (see section 2.6.1). For all QCs a known volume (3m1, which equals 
'75 o/o of the total
volume) of the organic solvent was transferred during the extraction procedure. The
unextracted QCs were prepared to contain the same concentration as the theoretical
concentration of the given volume extracted QCs (75%). The peak heights of the extracted
and the unextracted samples could then be compared to determine the percent recovery of
each metabolite and the internal standard.
The recovery of noroxycodone and oxymorphone was more than 90Yo, and did not appear
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to be different over the concentration range studied. The recovery of hydromorphone (HM)
was lower (mean 75o/o) than that obtained for noroxycodone and oxymorphone, and was
identical to that previously reported by Hutchinson (1999) when using the same extraction
method in the study of hydrocodone metabolism. Tables 12-14 show the recoveries
obtained for noroxycodone, oxymorphone and internal standard (HM).


























Table 13 Percent recovery for Oxymorphone after extraction.





















Table 14 Percent recovery for internal standard (hydromorphone) after extraction.
HQC MQC/LQC

















HQC samples were injected at a different volume to MQC and LQC, and consequently the
peak height was different for the internal standard (hydromorphone) between HQC and
MQC/LQC. These are therefore presented in two different columns even though the





Two different oxycodone concentrations (500 and 5000pM) were incubated with
microsomes with protein concentrations varying from 0.064 to I.026 mg/ml (conc. in
incubation mixture). The study was performed in duplicate.
As a result of the protein dependency study 125pg protein/incubation (0.5mg proteirlml)
was selected as the optimal protein concentration for further studies. This protein
concentration was in the linear portion of the curve relating metabolite forrnation with
protein concentration, and both metabolites were formed at levels that could be quantified
accurately from a calibration curve (Figure 8).
Figure 8 Metabolite formation at various microsomal protein concentrations (mg/ml) at two different
OC concentrations. Each data point represents mean+SD (n=2).
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2.7.2 Incubation timedependency study
Two different oxycodone concentrations (500 and 5000pM) were incubated with
microsomes and the incubation time ranged from 10 to 120 minutes. The study was
performed in duplicate.
Figure 9 shows the relationship between incubation time and metabolite formation from 10
to 120 minutes. The curve did not clearly plateau before 120 minutes. The incubation time
for further incubations was set at 60 minutes since this was well within the linear portion of
the curve, and since both metabolites were formed at levels that could be quantif,red
accurately from a calibration curve.
Figure 9 Metabolite formation in human liver microsomes at various incubation times at two different
OC concentrations. Each data point represents mean+SD (n=2).
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2.7.3 Influence on metabolileformation by substrøte solvent pH
Oxycodone was diluted in incubation buffer and in MilliQ water. Both dilutions were
incubated with two livers (HLM#21 and #31) at two different oxycodone concentrations
(500 and 2000pM) in order to compare the extent of metabolite formation.
Higher formation of both metabolites was observed when oxycodone was diluted in
incubation buffer as compared to oxycodone diluted in water (Figure 10).
Figure 10 Comparison of metabolite formation when incubation buffer (pH=7.6) and water (pH:5.7)
were used as solvents for substrate (OC). Metabolite formation is expressed as peak height ratio of
metabolite to internal standard. Each column represents the mean of duplicate. Microsomes from two





























The pH in both the incubation buffer dilution and in the water dilution'\Mas measured, and
it was found to be 7.6 and 5.7 respectively. Since the formation of metabolites appear
sensitive to substrate solvent pH, it was decided to use oxycodone diluted in buffer since
this should protect against any pH changes during the experiment, and since the pH was
close to physiological pH.
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3.7 Assøy performønce duríng kinetíc studies
It was necessary to increase the volume of internal standard in the kinetic and expressed
eîzyme studies compared to the validation (70pr1 versus 60pl). This alteration was made to
facilitate internal standard peak detection in the samples that contained high OC
concentration during the kinetic and expressed enzyme studies where the volumes injected
onto the HPLC system were low (15p1). As a consequence of this internal stan&rd volume
change, the mean slope of the standard curves changed to a different value (NOC - 0.089
and OM - 0.25I) for the kinetic and expressed enzyme studies compared to the validation
data (NOC - 0.136 and OM- 0.348) (2.6.1.1), but the slope changed less than 10 % within
these studies. The variability of QC data as precision and accuracy was less than 10 %. In
contrast, the lowest NOC standard showed substantial variability, and this standard had to
be excluded in four of the assays since it did not med the assay criteria. However, the
formation of NOC was noÍnally well above the lowest standard, and therefore excluding
this standard did not prevent quantification of any of the samples. Table 15 and 16
summarize the ongoing assay performance.















Mean 49.3 912 2.42
sD 1.24 0.56 0.19
%Cv 2.51 6.14 7.79o/oÑccuracy gB.7 91.3 96.8
n: 20 20 20
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3.2 Microsome properties and genotype døtu
All of the prepared microsomes had acceptable protein and P450 concentrations. Table 17
summarizes the properties and the CYP2D6 and CYP2C19 genotype data of the
microsomes used in this project. The patient data are also presented individually in
Appendix A.


















































The kinetics of NOC and OM formation were determined for ó CYP2D6 extensive
metabolizers and I CYP2D6 poor metabolizq (Table 17). The kinetic profiles and Eadie-
Hofstee plots for all livers are shown in Appendix B.
3.3. 1 Oxymorphone formøtion
The Eadie-Hofstee plots were curvilinear for all livers (including the PM liver), indicating
involvement of two or more enzymes (Figure 11 and l2). The two enzyrne Michaelis
Menten model were therefore fitted to the data. The data from HLM#I1 and#23 only fitted
the Michaelis Menten model with l/y*y weighting. This weighting was therefore chosen
for all the OM kinetic data for consistency through the results. Sum of squares and
coefficient of determination (r2) in the remaining HLM did not change substantially with
the use of l/y*y compared to the results obtained with l/y weighting.
The Michaelis Menten plots did not plateau in all livers, indicating that OM formation had
not saturated within the OC concentration range used (e.g. PM in Figure 12). Several of the
values for K¡a2 were also above the top OC concentration (20mM) (Table 18), which makes
these estimates inaccurate. Ideally higher OC concentrations should be used to achieve
saturation of OM formation, but this was not possible since the OM and NOC peaks
obtained in the HPLC analysis could not be resolved at OC concentrations higher than
2OmM.
It was evident from the mean intrinsic clearance values obtained from the EMs that the
high affinity enzyme involved in the formation of OM was responsible for 9+98% of the
overall OM formation in the EMs.
Kr'r values obtained for liver #24 (PM) were within the range of those from the EMs.
However, the maximum velocity of metabolite formation (V'**1) and intrinsic clearance
(Clintr) for the high affrnity enzyme were substantially lower in the PM (Table 18).
Figure 11 shows a typical kinetic profile and Eadie-Hofstee plot of OM formation in an
EM, while Figure 12 shows the results from the PM. Table 18 summarizes the kinetic data
for OM formation for all livers.
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Figure 11 Typical kinetic profile and Eadie-Hofstee plot of OM formation in CYP2D6 EM liver
Chapter 3
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tr'igure 12 Kinetic profile and Eadie-Hofstee plot of OM formation in CYP2D6 PM liver.























































































The Eadie-Hofstee plots were linear for most livers, indicating involvement of only one
enzymo The one eîzyme Michaelis Menten model was therefore fitted to the data. Liver
#24 (PM) gave results that were within the range for the EMs. Liver #23 and #31 had
Eadie-Hofstee plots that were slightly curvilinear, and for these two livers both the one and
the two enryme model fitted the data adequately. The one enzyme model was used since
there was no substantial difference in the fit. Liver #35 appeared to have an Eadie-Hofstee
plot that curved back on the v/s axis, but no other model than the one enzyme Michaelis
Menten model fitted the data.
Table 19 summarizes the kinetic data of NOC formation for all livers, while Figurel3 A
shows a typical kinetic prof,rle and Eadie-Hofstee plot of NOC formation.





#5 74t2 12.9 515
#tt 1825 2.52 724
#2r 939 2.67 3s2
#23 280 298 94
#3t 160 2.88 55
#35 432 3.0s 142
#24-P}Í4 493 t.52 32s
Mean 1649 4.07 324
+sD 2603 3.92 252
%cv r57 96.4 78.0
Median 493 2.88 325
Range 160-7412 1.52-12.9 55-724
Due to problems with substantially higher formation of NOC in some of the livers, the
weighting of the data when performing the regression analysis varied. In HLM #5, 11 and
2l no weighting was better than lly andlly*y since the top six concentrations of OC had
been incubated with alterations to the method (section 2.3.3.7), and in different assays than
the lower concentrations. The fitting of the data for these livers was not as accurate as the
data obtained from the livers where the procedures were kept consistent and within one
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A: Typical kinetic profile and Eadie-Hofstee plot of NOC formation.
B: Kinetic profile and Eadie-Hofstee plot from liver where the top 6 OC concentrations had been
incubated in separate assay.
A discontinuity v/as seen \¡/here the curve transferred from data obtained from two different
assays, and the error was magnified in the Eadie-Hofstee plots (Figure 13 B). However, the
effor appeared as a fixed error since the slopes of the Eadie-Hofstee plots \Mere consistent
between the two halves of the curves. The kinetic studies in HLM #23, 31,35 and 24 had
been carried out with no alterations to the method, and for these livers l/y weighting of the
data resulted in the best fit.
The results from HLM#5 were inconsistent with the results obtained from the rest of the
livers. The K¡a value \üas more than four times higher for HLM*S compared to the highest
Krr¡ calculated for the other livers.
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3.3.3 Total íntrinsic Clearance
Substantial variability was seen for the total intrinsic clearance of OC when the individual
Clint values for OM and NOC were summed (Table 20)'
clearancevaluesofOCtoOMandNOC(pl'/hr/mg)'OMhigh:highaffnity
formation. oM low: low affrnity enzyme involved in oM formation.
Table 20 Total intrinsic
enzyme involved in OM

























Total Clmt 626 750 422 145 81 187 330 363!252
NOC formation contributed more to the total clmt than oM formation (Table 21)'
Contribution to the total intrinsic clearance of oxycodone from the individual O- and N-
demethylation pathways are listed in Table 2l and illustrated in Figure 14'
Table 21 Percent contribution to the total oxidative metabolism by the NOC and OM 
(high and low
affinity enzyme) PathwaYs.
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Human liver microsomes (internal no.)
Figure 14 Extent of involvement of different metabolic pathways in OC oxidative metabolism'
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3.4 Chemícøl ínhíbítíon studíes
3.4.1 CYP isoform speciJic chemícul inhibítíors
3.4. 1. 1 Oxymorphone formation
Figure 15 and Table 22 show the results from the chemical inhibitor studies in three
CYP2D6 EMs when the OC concentration was similar to the Kur of OM. Each bar in
Figure 15 represents three livers (meantSD). The variation within all duplicates was less
than l0o/o.
Figure 15 Percent inhibition of OM formation by CYP isoform specific chemical inhibitors (compared
to control samples) in CYP2D6 EMs (n=3). Each bar represents the mean inhibition in three livers,
while the error bars refer to SD. Statistical significance is indicated with * for p<0.05, ** for p<0.01
and *** for p<0.001.
Sulphaphenazole (p:0.129), chlorzoxazone (p:0.065), TOA (p:0.227) and Smephenytoin
(p:0.393) did not inhibit OM formation (p>0.05).
OM formation was inhibited by quinidine (CYP2D6 inhibitor) in a concentratior¡
dependent manner, although the SD between the three livers was large. The variability was
mainly due to substantially less inhibition in HLM#ll (Table 22). Dextromethorphan,

























































Table22 Percent inhibition of OM formation by CYP isoform specific inhibitors in the individual livers
tested.
% Inhibition















































































Furafylline, which is known to inhibit CYPlA2, inhibited formation of OM by 37% in the
EMs when the inhibitor concentration was 100¡rM (p:0.0001). The inhibition of OM
formation was still around 29o/o when the furafylline concentration was reduced to 25¡rM
(p:0.002). At this concentration, furafylline is highly specific towards CYP1A2.
DDC (100pM) inhibited OM formation by 24o/o, and the inhibition was significant
(p:0.019). The formation of OM was also inhibited by ketoconazole. Although the
inhibition was low (ll%), statistical significance was seen (p:0.043). Induction of OM
formation \ilas seen with coumarin (llYo), and the effect was statistically significant with
p:0.027.
The chemical inhibitor studies were also carried out at a concentration near the Knr for
NOC for the purpose of investigating NOC formation. The results for OM from these
studies are supportive of the results described in this section, and can be found in
Appendix C.
The results from the chemical inhibitor study in the CYP2D6 PM were inconclusive. OM
formation v/as very low, and it was therefore difficult to detect the difference between the
control and the inhibitor samples accurately. Substantial variability within the duplicates
was also noted. The results are presented in Appedix C.
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3. 4. 1. 2 N oroxy co do ne for m atío n
Figure 16 and Table 23 show the percent inhibition of NOC forrnation in the chemical
inhibitor studies when the OC concentration was similar to the K¡a of NOC. Each bar in
Figure 16 represents three CYP2D6 EM livers (mean+SD), except for quinidine 1OpM and
ketoconazole 10pM where only two livers were used. The variation within all duplicates
was less than ljYo.
Figure 16 Percent inhibition of NOC formation by CYP isoform specific chemical inhibitors (compared
to control samples) in CYP2D6 EMs (n=3, Quin 10pM and Keto 10¡rM n:2). Each bar represents the
mean inhibition in three(/two) livers, while the error bars refer to SD. Statistical signifÌcance is
indicated with * for p<0.05, ** for p<0.01 and **'r for p<0.001.
Furafylline (p:0.061), coumarin (p:0.422), sulphaphenazole (p:0.063), $mephenytoin
(p:0.189), dextromethorphan (p:0.848) and quinidine at 10FM (p:0.328) did not
significantly inhibit NOC formation (p>0. 05).
Ketoconazole, a potent and selective CYP3A4 inhibitor, inhibited NOC formation in a
concentration-dependent fashion. At an inhibitor concentration of 100pM, NOC formation
was almost nonexistent. TOA, another CYP3A4 inhibitor, resulted in650/o inhibition at an
inhibitor concentration of 10pM. Quinidine reduced NOC formation to 55%o of the control

























90 %. Chlorzoxazole also inhibited NOC formation signif,rcantly (20ti % inhibition,
p:0.038).
Table 23 Percent inhibition of NOC formation by CYP isoform specific inhibitors in the individual
livers tested.
% Inhibition























































The NOC data obtained from the chemical inhibitor studies where OC was incubated at a
concentration near the Kvrr of OM were also interpreted. These results can be found in
Appendix C. They are supportive of the results described in this section and also include
one CYP2D6 PM.
3.4.2 Solvent inhibition
3. 4. 2. 1 Oxymorphone formøtion
Figure 17 shows the effects of solvents used in the chemical inhibitor studies on OM
formation when the OC concentration was similar to the K¡a1 of OM. Each bar in Figure 17
represents the mean of three CYP2D6 EM livers, while the error bars represent the SD
between the livers. Percent variability within the solvent duplicates was less than l0o/o.
Methanol (MeOH) inhibited the formation of OM signif,rcantly (p<0.05), while induction
of OM formation was observed in the presence of 0.83 % DMSO (p<0.01). ACN showed
signiflrcant (p<0.05) induction at a concentration of 2.5%o,but insignif,rcant induction and
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substantial variability \¡/as seen for ACN at l0 %o. Appendix C holds the results from the
study where OC concentration was near the Krr¡ of NOC. These results were similar, but
DMSO induction could not be seen.
Figure 17 Inhibition of OM formation by solvents used in the chemical inhibitor studies (n:3).
3. 4. 2. 2 Norory co do ne formøtíon
Figure 18 shows the effects of solvents used in the chemical inhibitor studies on NOC
formation when the OC concentration was similar to the Kn¡ of NOC. Each bar in Figure 18
represents three CYP2D6 EM livers (meantSD). Percent variability within all the solvent
duplicates was less than I0%o.
Figure 18 Inhibition of NOC formation by solvents used in the chemical inhibitor studies (n=3).
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ACN and MeOH inhibited the formation of NOC by 33116 and 24+12 percent
respectively, while DMSO and water had little effect. However, the inhibition was not
statistically significant for any of the solvents. The results from the study where OC
concentration \¡/as close to the K¡a of OM can be found in Appendix C. These results were
similar to the results presented in Figure 18.
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3.5 Antíbody ínhibition studíes
3.5.1 Monoclonal antibodies
3. 5. 1. 1 Oxymorphone formation
Figure 19 shows the effect of various CYP isoforrn monoclonal antibodies on OM
formation when the OC concentration v/as similar to the Kv¡ of OM. Each bar represents
three CYP2D6 EM livers (meaniSD).
CYP1A2 (8uU100ug prot)
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Figure 19 Percent OM formation compared to control samples in 3 CYP2D6 EM livers (mean+SD) in
the presence of monoclonal CYP antibodies. Statistical signifìcance is indicated with ** for p<0.01.
(prot: protein, ul,=¡rl, ug=pg)
Monoclonal antibodies against CYP2D6 inhibited OM formation, but the inhibition \¡/as
not antibody-concentration dependent. The difference between the two antibody
concentrations used was rather small, but the assay \¡/as not repeated at other antibody
concentrations due to the expense of using antibodies. No other antibodies (CYPlA2,
CYP2El, CYP3A4) inhibited OM formation.
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3. 5. 1. 2 Norory co do ne Íorm atio n
Figure 20 shows the effect of various CYP isofoÍn monoclonal antibodies on NOC
formation when the OC concentration was similar to the Krr¿r of OM. Due to the expense of
using antibodies the study was not carried out at a concentration similar to the K¡aof NOC.
Each bar in Figure 20 represents three CYP2D6 EM livers (meanJSD).
CYP1A2 (8uU100ug prot)
CYP2DO (2.4uU1 00ug prot)
CYP2D6 (4uU100ug prot)
CYP3A4 (2.4uU1 00ug prot)
CYP3A4 (4uU100ug prot)
CY P 2E1 (2.4uU 1 00ug prot)
CYP2E1 (8uU100ug prot)
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7o formation of control
Figure 20 Percent NOC formation compared to control samples in 3 CYP2D6 EM livers (mean+SD) in
the presence of monoclonal CYP antibodies. Statistical significance is indicated Ì/ith *rstr for p<0.001.
(prot: protein, ul,=pl, ug=pg)
Antibodies towards CYP3A4 inhibited NOC formation in an antibody concentratioru
dependent manner. The other antibodies tested did not have any signifrcant effect on NOC
formation (p>0.05).
3.5.2 LKM| antibodies (CYP2D6)
3. 5. 2. 1 Oxymorphone formatìon
Concentration dependent inhibition was seen for OM formation when LKM1 antibodies
directed against CYP2D6 was included in the incubation mixture (Figure 21). The
maximum inhibition seen with the highest antibody concentration (2¡rll50pg protein) was
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50 yo, and the inhibition was statistically significant for all the antibody concentrations.











X'igure 21 Oxymorphone formation in 3 livers (meantSD) in the presence of LKM1 antibodies.
Statistical significance is indicated with * for p<0.05 and ** for p<0.01.
3. 5, 2. 2 Norory co done formatìo n
NOC formation was similar to 90 Yo of the control samples when LKM1 antibodies
directed against CYP2D6 were included in the incubation mixture (Figure 22). Although
the inhibition observed was statistically signihcant, no antibody-concentration dependent





0 20 40 60 80






Figure 22 Noroxycodone formation in 3 livers (meantSD) in the presence of LKM1 antibodies.
Statistical significance is indicated with * for p<0.05, ** for p<0.01. and *'t* for p<0.001.
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3.6 Expressed CYP enzymes
3.6.1 Metabolite formation from OC in ø panel of expressed enzymes
Figure 23 shows NOC and OM formation when OC was incubated with various expressed
enzymes. Eachbar represents a duplicate incubation (meanlSD), except for OM formation





































Figure 23 tr'ormation of OM and NOC in the presence of expressed CYP enzymes.
3. 6. 1. 1 Oxymorphone formation
Formation of OM was found with CYP2D6 microsomes and supersomes, as well as with
the CYP2C19 supersomes (Figure 23). One single sample had detectable formation of OM
with the presence of CYP3A4 microsomes, but OM formation was not seen in further
studies with CYP3A4 expressed enzymes.
8l
3. 6, 1. 2 Nororycodone formation
NOC formation was seen when OC was incubated with CYP3A4 microsomes, and also to a
lesser extent with CYP2C19 supersomes (Figure23).
3.6.2 Kinetic studies in expressed enzymes
Kinetic prof,rles were obtained for OM formation in CYP2D6 microsomes and NOC
formation in CYP3A4 microsomes. A range of OC concentrations were also incubated with
CYP2CI9 supersomes, but no kinetic model fitted the formation data for either of the
metabolites.
3.6.2. 1 CYP2D6 microsomes
A kinetic prof,rle of OM formation by CYP2D6 microsomes \ryas obtained using eight
concentrations of OC (35-525 pM). The data fitted the Michaelis Menten one enzyme
model (Figure 24) with a Ku of 57.8 pM and Vmax of 8.63 nmol/mglhr. The K¡a was at
the lower end of the range that was found in the kinetic studies for the human liver
microsomes (Krr¡r 57.2-258 ¡rM). The Eadie-Hofstee plot formed a straight line as expected
(Figure 24) since only one eîzyme was present.















Figure 24 Kinetic profile and Eadie-Hofstee plot for OM formation in CYP2D6 expressed microsomes.
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3. 6.2.2 CYP3A4 miuosomes
Six concentrations of OC (525-7000 ¡rM) were used to produce a kinetic prof,rle of NOC
formation in CYP3A4 expressed microsomes. The data obtained fitted the Michaelis
Menten one enzyme model (Figure 25) with a Ky of 2.4 mM and Vmax of 240.3
nmol/mglhr. The K¡4 obtained was within the range (1.52-12.9 mM) and close to the
median K¡a value (2.9 mM) obtained in the human liver microsome kinetic studies. The
Eadie-Hofstee plot indicated a straight line (Figure 25), which confirms the presence of a
single enzyme only.
Michaelis Menten kinetics CYP3A4 NOC
a a
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Figure 25 Kinetic profile and Eadie-Hofstee plot for NOC formation in CYP3A4 expressed
microsomes.
3.6.3 Inhibitíon oÍ metabolite formation by S-mephenytoin in CYP2C19
expressed enzymes
Formation of NOC and OM was only inhibited by 20-30% when Smephenytoin
(CYP2C19 chemical inhibitor) at 100¡rM was incubated concomitantly with OC with the
CYP2C19 supersomes (Figure 26). This test was performed since the chemical inhibitor
studies did not support involvement of CYP2C19 for either of the metabolites in contrast to
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Figure 26 Percent inhibition of OM and NOC formation when S-mephenytoin (100pM) was incubated




An unidentif,red peak with a retention time of about 8 minutes was seen after incubation of
OC with human liver microsomes (Figure 27). This peak was negligible in Figure 6
(Chapter 2) since its appearance becomes increasingly prominent with higher substrate
concentrations. The chromatograph presented in Figure 6 shows incubation with only
300pM substrate, while the substrate concentration in Figure 27 was 500pM.
Noroxymorphone, a metabolite of OM, could be excluded as the suspected compound since
it had a retention time of about 5 minutes when injected onto the HPLC.
Absorbance (mAbs)
8 min
Figure 27 IJPLC chromatograph following incubation of 500pM OC in HLM#I1. Unidentified peak
indicated with arrow (see Figure 6, Chapter 2).
Formation of the unidentified peak was evident in the chemical inhibitor studies where the
OC concentration was near the K¡a of NOC formation (relatively high substrate
concentration), and it was possible to detect inhibition of its formation by some of the
inhibitors. Therefore some conclusions on CYP450 involvement could be made. The peak
was also present in the expressed eîzyme studies. No formation of the unidentified
compound was seen in the antibody studies, and this was probably due to the low OC









Quantification of formation was not possible for the unidentif,red metabolite, therefore
velocity (v) was expressed as peak height ratio (PHR)/mg protein/hr. Knr could then be
determined by plotting this v value against substrate concentration in the Michaelis Menten
regression. The Eadie-Hofstee plots were in most cases slightly curved, while for HLM#35
it was curving back at the v/s axis. This was also seen for NOC formation in this liver. The
one enzyme model could be fitted to the data from all the liver microsomes, but for 5 of 7
livers the two enzyme model also fitted the data with a better fit. The Kr,,r wæ
5.96f2.00mM (meantSD) when the data were f,rtted to the one enzyme model. The two
enzyme model resulted in K¡l values of 1.90+3.O2rnNI and 17.6t15.9mM (n:5).
3.7.2 Chemical inhibitors
Formation of the unidentif,red peak was inhibited signif,rcantly (p<0.05) by quinidine
(100pM), DDC (100¡rM), TOA (10pM), chlorzoxazone (100pM) and ketoconazole (100
and 10pM) (Figure 28).
Figure 28 Percent inhibition of unidentifìed metabolite by CYP isoform specifìc chemical inhibitors in
CYP2D6 EMs (n:3). Each bar represents the mean inhibition in three livers, while the error bars refer
































Formation of the unidentified metabolite was seen with all the expressed enzymes tested.
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The aims of this study were to investigate the enzpe kinetics of the formation of
noroxycodone and oxymorphone from oxycodone in human liver microsomes, and to
identify the P450 isoform(s) involved in these two metabolic reactions. It was hypothesized
that CYP3A4 is the major isoform involved in formation of noroxycodone, and that
CYP2D6 plays a major role in oxymorphone formation. In order to satisfy the aims of the
study it was important to use an accurate and precise method for quantif,rcation of
noroxycodone and oxymorphone in human liver microsomal preparations.
Previous methods for quantifîcation of oxycodone and its metabolites include HPLC with
electrochemical detection (Smith et a1.,199t-oxycodone; Otton et a1.,1993-oxymorphone)
and gas chromatography/mass spectrometry (Kaiko et ãI., l99G
oxycodone/noroxycodone/oxymorphone). A new HPLC method with IJV detection was
developed for quantiflrcation of the O- and Ndemethylated metabolites of hydrocodone in
this laboratory (Hutchinson, 1999). This method combined the use of sodium perchlorate as
an ion pairing agent and a C18 rocket column to allow separation of hydrocodone and the
metabolites even at high substrate concentrations. Due to the structural similarity of
oxycodone and hydrocodone (Figure 3) it was decided to try this assay method for the
quantification of noroxycodone and oxymorphone, and only minor changes to the method
were needed. The only major problem was separation of noroxycodone from oxycodone at
substrate concentrations above 3500pM. This problem was dealt with by reducing the
volume injected onto the HPLC, and, for some of the livers, by reducing the incubation
volume for the respective samples. The HPLC run time was long (60 minutes), and most of
the assay-runs lasted for up to 2 days. In spite of this, high precision and accuracy were
obtained for inter- and intra-day variability, for both the standard curves and the quality
controls, in all the assays performed.
Preliminary studies by Brauer and Ralfkiær (1998) demonstrated that the extraction of
oxycodone and its metabolites, noroxycodone and oxymorphone, from the incubated
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samples was necessary since unextracted samples caused interfering peaks and noisy
baseline in the chromatographs, as well as repeated blockage of the HPLC prefilter. Brauer
and Ralfkiær (1998) also tested various solvents for extraction and found that
dichloromethane resulted in the best recovery of noroxycodone, oxymorphone and
hydromorphone (internal standard). Their method for extraction was used in the present
study, and a recovery of more than 90 %o was found for both oxymorphone and
noroxycodone.
Er.zyme kinetic studies for the metabolism of oxycodone have not been published in
international journals previously, but very preliminary kinetic studies have been conducted
by Brauer and Ralfkiær (1998) in this laboratory. Kinetic studies are needed in order to
determine the extent of the different metabolic pathways using the intrinsic clearance
values (V.u*/K¡a). It is also necessary to conduct kinetic studies prior to CYP inhibition
studies in order to obtain an estimate of which substrate concentration(s) should be used in
the incubations (should be similar to K¡a). Different K¡a and Vn,,u* values were obtained for
oxymorphone and noroxycodone formation, indicating that different enzymes catalyse O-
and N-demetþlation of oxycodone. The two pathways will therefore be discussed
separately.
The Eadie-Hofstee plots obtained for oxymorphone formation \Mere curved, and the two
enzyme Michaelis Menten model fitted the data for all the livers (6 EMs and 1 PM). This
finding indicates that there are at least two enzyÍres involved in the O-demethylation of
oxycodone. The mean values obtained for V*u* in the EMs were 5.56+3.17 (Vnu*¡) and
31.0L28.7 (V,u*z) nmol/hr/mg protein, while the Ku values obtained were 143-f84 FM
(K¡a1-high affinity) and29.3!34.1 mM (K¡a2-low afhnity), respectively. The K¡a1 is slightly
lower than the K¡a value obtained (262X81¡tM, tr4 EM) from an unpublished study
conducted in this laboratory (Brauer and Ralfkiær, 1998), but they obtainedtheir kinetic
parameters by fitting the one enzyme Michaelis Menten model to the data rather than the
two enzyme model.
The K¡a2 obtained from 4 of 7 livers, as well as the mean for the EMs, was above the
highest oxycodone concentration used. This suggests that oxymorphone formation in the
89
Discussion
respective livers was not saturated at the substrate concentrations used, and the
corresponding Michaelis Menten plots further supported this, as the curves did not plateau.
It can therefore be concluded that the estimations of the kinetic parameters obtained for the
low affinity enzyme are rather inaccurate.
Intrinsic clearance values v¡ere a mean of 42.8+16.1 fl,lfulmg for the high aff,rnity enzyme
(Clintr) in the EMs, while the values obtained for the low affinity erLzyme was only
1.92+1.19 p"llhrlmg (Cli",z). These data demonstrate that the low affinity enzyme in EMs
only contributes about 4.3 % to the total oxymorphone formation, and that the inaccuracy
of the K¡a2 values was not likely to be important.
Previous studies have associated CYP2D6 with the O-demethylation of oxycodone (Otton
et al., 1993; Heiskanen et al., 1998). The CYP2D6 PM was therefore expected to have one
less enzyme involved in ox¡rmorphone formation compared to the EMs. However, the two
enzyme Michaelis Menten model flrtted the data from the PM better than a one enzyme
model, and the Eadie-Hofstee plot was clearly curvilinear. The Krr¡lvalue obtained for the
PM was in the same range as the K¡a1 obtained for the EMs, while the intrinsic clearance
for this high affinity enzyme was substantially lower in the PM. The PM liver used in this
study had been genotyped as CYP2D6*4 (homozygous), which corresponds with no
CYP2D6 activity (Daly et a1., 1996). Thus, the high affinity enzpe seen in the PM was
not CYP2D6 with decreased activity, although the K¡a value indicated this. It is possible
that more than two high affinþ enzymes are involved in oxymorphone formation for EMs.
Fitting of a three erzyme Michaelis Menten model to the EM data was attempted without
success. However, if Krr,r¡ is similar to one of the other Kryr values the model will not be
able to determine its value. Such a similarity was suggested in the K¡a1 value obtained for
the PM.
The kinetic studies for N-demethylation were not conclusive to whether one or more
enzymes are involved. Linear Eadie-Hofstee plots were obtained for most of the livers, but
the Eadie-Hofstee plots for two of the livers curved slightly. Both the one and the two
enzyme Michaelis Menten model fîtted the data from these two livers,but the improvement
in fit was not substantial. Eadie-Hofstee plot that curved back on the v/s axis was obtained
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for one single liver, but this liver only fitted the one enzyme Michaelis Menten model. It
was decided to use the one enrqe Michaelis Menten rrndel, since this fitted the data for
all the livers, and since the statistical law of parsimony states that the simplest model
should be used when several options of equal value are available. The median value
obtained for Vn'u* was 493 nmol/hr/mg protein (range: 160-7412), while the median Ku
value obtained was 2.88 mM (range: 1.52-12.9). The mean values obtained for V'u* and
K¡a v/ere not representative since the kinetic parameters obtained from one liver (HLM#5)
were highly untypical. Extensive and poor metabolizers with respect to CYP2D6 had
similar enzyme kinetics for noroxycodone formation. In comparison to the present studies,
Brauer and Ralfkiær (1998) charucteized the formation of noroxycodone by a V*u* of
1598+347 nmol/hr/mg protein and a K¡a of 1.60+0.22 mM in 4 livers.
Both the K¡a and the V'u* values obtained for HLM#5 were 4 times higher than the second
highest obtained K¡a and Vn'u* in the present kinetic studies for noroxycodone. HLM#5 was
one of the livers with high noroxycodone formation, requiring adjustments in the
incubation method as described in section 2.3.3.1, and a higher Vn.u* was therefore
expected. However, the K¡q value should not differ substantially from the other livers if the
same enzyme catalyses the reaction. For example, the Ku obtained from HLM#l1 was
close to the median although the intrinsic clearance for HLM#I1 was the highest of all the
obtained intrinsic clearance values. It is difficult to explain why oxycodone kinetics in
HLM#5 deviated from the kinetics in the other livers. The patient was not receiving any
enzyme inducing drugs. Moreover, studies on hydrocodone and methadone in the same
liver did not show unusual kinetics, even though the same enzyme (CYP3A4) is involved
in the N-demethylation of these two drugs (Hutchinson, 1999; Foster et al., 1999). The
reason for this finding therefore remains unknown.
Cooperativity in oxidation has been reported for CYP3A4. This is, when binding of a
substrate in a particular conformation can facilitate oxygen activation and thereby enhance
catalytic activity (Ueng et al., 1997). One feature of this model is the sigmoidal curve for
the formation rate, with corresponding Eadie-Hofstee plot that shifts back on the v/s axis
(to the left when v/s is x axis) (non-linear). The cooperativity model can therefore be an
explanation for the non-linear Eadie-Hofstee plot obtained for noroxycodone formation in
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one liver (HLM#35). The Eadie-Hofstee plot obtained for the unidentified peak (section
3.7.1) in the same liver also reflected sigmoidal kinetics, and from the CYP identification
studies this substance appeared to be CYP3A4 dependent. It has been shown that lipid
soluble organic compounds, particularly bases, bind non-specifically to microsomal
membranes. If the substrate concentration in a microsomal incubation is in the saturable
ratTge, and if the non-speciflrc binding is not corrected for, sigmoidal formation kinetics
may occur (Mclure et al., 2000). This could be another explanation for the nonlinear
Eadie-Hofstee plot for HLM#35.
The total intrinsic clearance of oxycodone to noroxycodone and oxymorphone was highly
variable (range: 81-750 ¡tJlhrlmg protein), and much of this variability could be accounted
for by the variable contribution from the N-demetþlation pathway (range: 5t
724 ¡illfulmg protein). The variability in intrinsic clearance was similar when excluding
HLM#5.
Information on the enzymes involved in a drug's metabolism is now required during drug
development, since knowledge from in vitro enzyme kinetics and inhibition studies can
provide a guide to which in vivo drug interaction studies need to be conducted. However,
no previous studies have systematically tested the enzyme(s) involved in the oxidative
metabolism of oxycodone, and the present study therefore aimed to identify which
cytochrome P450 enzyrnes are involved in the primary oxidative metabolism of
oxycodone.
Otton et al. (1993) studied oxycodone metabolism in vitro using human liver mrcrosomes
from 1 CYP2D6 EM and I CYP2D6 PM. They found that ox¡rmorphone formation was
signif,rcantly inhibited by quinidine (a potent CYP2D6 inhibitor) in the CYP2D6 EM, and
that oxymorphone formation was substantially smaller (about 1/5) in the PM comparecl to
the EM (K¡a and V'nu* values v/ere not reported). It was therefore concluded that CYP2D6
is important in oxycodone O-demethylation. Heiskanen et al. (1998) supported this
involvement as inhibition of CYP2D6, using quinidine, effectively blocked the formation
of oxymorphone after administration of oxycodone in 10 healtþ CYP2D6 EMs. CYP2D6
involvement in oxycodone O-demetþlation is further supported by studies on structurally
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similar drugs (codeine, dihydrocodeine, hydrocodone), where CYP2D6 involvement has
been documented (Mortimer et a1., 1990; Kirkwood et al., 1997b; Hutchinson, 1999).
Based on these previous studies, it was hypothesized prior to the present study that
CYP2D6 is involved in the O-demetþlation of oxycodone. This involvement was
confirmed in the present study using CYP specific chemical inhibitors, antibody inhibitors,
CYP expressed enzymes, and comparing the kinetic studies from CYP2D6 EMs and a PM.
Strong evidence for CYP2D6 mediated O-demetþlation of oxycodone was found in the
CYP specif,rc chemical inhibitor studies, as significant inhibition was observed with
quinidine and dextromethorphan. Dextromethorphan and quinidine are both CYP2D6
inhibitors, and therefore useful tools in the determination of CYP2D6 involvement in
metabolic reactions (Schmider et al., 1997; von Moltke et al., 1998; Newton et al., 7995;
Sai et al., 2000).
Quinidine potently inhibited oxymorphone formation in a concentration-dependent manner,
with almost complete inhibition at an inhibitor concentration of 100¡rM. Potent inhibition
was also seen in HLM#31 and HLM#35 at inhibitor concentrations of l¡rM (77 and89 %)
and 0.1¡rM (70 arrd 73 %). However, the variability in quinidine inhibition was large for
the three livers due to less potent inhibition in HLM#I1 (1pM- 37 %o and 0.1¡.rM -22%).
Dextromethorphan inhibition was also lower for this particular liver. Therefore, the
inhibition studies suggest that HLM#ll is less dependent on the CYP2D6 pathway
compared to HLM#31 and HLM#35. This is not in accordance with the kinetic studies for
oxynorphone formation, as HLM#31 and HLM#ll had similar clearance values for the
high aff,rnity enzyme.
The studies of the effect of solvents on oxymolphone formation lend further support to the
involvement of CYP2D6 since DMSO significantly induced oxymorphone forrnation by 25
o/o. According to Hickman et al. (1998) CYP2D6 is the only CYP450 isoform induced by
DMSO.
Monoclonal antibodies directed against CYP2D6 and LKM1 antibodies inhibited
oxymorphone formation significantly. The monoclonal antibodies inhibited oxymorphone
formation by 78 Yo at two different antibody-concentrations (2.4 and 4pll100¡rg protein).
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The lack of concentration dependency was probably due to the small difference between
the two antibody concentrations used. The maximum inhibition with LKMI antibody
positive serum was 50 Yo (with addition of 2¡i LKM1 positive serum per 50 ¡rg
microsomal protein), and the inhibition was antibody-concentration dependent. Kirkwood
et al. (1991b) used LKM1 antibodies to identify CYP2D6 involvement in the O-
demetþlation of dihydrocodeine, and almost complete inhibition (94 %) of metabolite
formation was found after addition of I Fl LKMI positive serum per 50 ¡rg microsomal
protein. However, the serum in this study had an antibody titre of 640, while the titre in the
present study was only 64.
CYP2D6 microsomes and supersomes showed substantial oxymorphone formation.
Furthermore, the one enzyme Michealis Menten model fitted the data obtained from the
kinetic study in the CYP2D6 microsomes, and the K¡,,rvalue (57.8pM) was within the range
of the K¡a1 values obtained from the human liver microsome kinetic studies (57 .2-258¡tM).
This strongly indicates that CYP2D6 is one of the high affrnity enzymes involved in
oxymorphone formation.
CYP2D6 involvement in oxymorphone formation was further supported by the results from
the human liver microsome kinetic studies since the clearance for the CYP2D6 PM via the
oxymorphone pathway was only 5.49 ¡illfulmg as compared to 44.75 ¡tUhrlmg (mean) for
the CYP2D6 EMs.
Furafylline at 25¡tM significantly inhibited oxymorphone formation by 29 %. A
mechanism-based mode of action for furafylline CYPlA2 inhibition has been shown, as
furafylline causes loss of CYP1A2 activity depending on pre-incubation time and presence
of cofactor (Kunze and Trager, 1993; Tassaneeyakul et al. 1994). Several studies have
shown that furafylline selectively inhibits CYPlA2 in vitro at concentrations up to 100¡rM
if furafylline is pre-incubated with NADPH and microsomes for at least 10 minutes prior to
addition of substrate (Tassaneeyakul et al. 1994; Newton et a1.,1995; Sai et aI.,2000). The
present chemical inhibitor study therefore suggests that CYPlA2 is involved in the
formation of oxymorphone. Induction of oxymorphone formation by acetonitrile in the
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solvent study could be an indication of CYPIA2 involvement as CYPIA2 is the orly CYP
isoform subject to potent induction by acetonitrile (Hickman et al., 1998), although the
induction seen in this study was rather inconsistent. However, CYPIAZ antibodies and
expressed CYP1A2 enzymes did not support the involvement of CYPlA2. Studies with
monoclonal antibodies and expressed enzymes are more reliable methods for CYP
identif,rcation than the use of chemical inhibitors (Shou et al., 2000; Sai et a1., 2000). An
involvement of CYPlA2 in O-demetþlation of oxycodone is therefore not likely.
Significant inhibition (24%) of oxymorphone formation was seen with 100¡rM DDC. This
inhibitor is acting on CYP2El, but several studies indicate that its selectivity is poor since
it also has been shown to inhibit cYPlA2/141, CYP2A6, CYP2B6, CYPZC8 and
CYP3A314 (Eagling et al., 1998; Chang et al., 1994). CYP2El antibodies did not support
CYP2EI involvement, and chlorzoxazone (CYP2E1 inhibitor) inhibition was insignificant.
It has been shown that CYP2El metabolises molecules with a low structural volume
(Lewis et al., 2000). It is unlikely that CYP2EI is involved in oxymorphone formation
since oxycodone has alatge molecular volume.
Involvement of CYP2C19 in the formation of oxymorphone was only supported by the
studies in expressed enzymes. However, antibodies towards CYPZCI9 were not available,
and the chemical inhibitor studies did not include a potent CYP}CL9 inhibitor. The potency
of S-mephenytoin as an inhibitor of CYPzClg was tested in the expressed enzymes, and it
was shown that it only inhibited oxynorphone formation by 27 o/o. Interestingly, Brauer
and Ralfkiær (1998) found 60 % inhibition of oxymorphone formation with $mephenytoin
in a CYP2D6 PM. Omeprazole, which is frequently used as an inhibitor of CYPZCI9 in
vitro, had to be excluded in the present study due to peak interferences in the HPLC
chromatographs. Consequently S-mephenytoin was the only CYP}CL9 specific inhibitor
used in the chemical inhibitor studies, and involvement of CYP2C19 in oxymorphone
formation could not be excluded on the basis of the inhibitor studies.
Ketoconazole (100pM) statistically significantly inhibited ox¡rmorphone formation, but
only by a mean of 1l %o. Although ketoconazole is a potent CYP3A4 inhibitor, it has been
shown that its CYP specificity is low at concentrations above l-2¡tM (Sai et al., 2000).
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CYP2D6, CYP2C9, CYP2C19 and CYPlAll2 are all inhibited by ketoconazole at 10qrM
when tested with known CYP450 substrates (Newton et al., 1995; Sai et a1., 2000).
CYP3A4 involvement in the O-demethylation of oxycodone was rnt supported by the
antibody studies, and only one sample in the expressed erLzyme studies with CYP3A4 had
detectable oxymorphone formation.
Coumarin induced the formation of oxymorphone signif,rcantly (l5o/o). Coumarin is a
selective inhibitor of CYP2A6 (Pelkonen et al., 2000), but no published research describes
CYP specihc induction by coumarin. Conclusions can therefore not be drawn from this
observation.
CYP3A4 has been related to the N-demetþlation of many opioids structurally related to
oxycodone. It has been shown that CYP3A4 is involved in the metabolism of codeine to
norcodeine (Caraco et al., 1996b; Yue and Säwe, 1997), and the same relationship has been
described for dihydrocodeine (Kirkwood et al., 1997b) and hydrocodone (Hutchinson,
1999). Due to the structural resemblance between these drugs and oxycodone, it was
hypothesized that CYP3A4 is involved in oxycodone N-demetþlation. However, no
previously published studies have attempted to identify its involvement. It was evident in
the present study that CYP3A4 catalyses oxycodone N-demetþlation, and the involvement
,was supported by all the CYP identif,rcation methods.
Several chemical inhibitors directed against CYP3A4 were used. TOA (10pM) inhibited
noroxycodone formation by 65%o. Chang et al. (1994) demonstrated that TOA is highly
selective for CYP3A if the correct experimental conditions (pre-incubation) are applied.
Moreover, a study by Newton and co-workers (1995) showed that TOA has high CYP3A4
selectivity in human liver microsomes at concentrations up to 400pM. Ketoconazole at
100pM almost completely abolished the formation of noroxycodone, and the inhibition
was also substantial (90%) when the inhibitor concentration was reduced to 10pM.
However, the inhibitory effect of ketoconazole was highly variable and insignificant at I
and 0.lpM. Several studies have shown that ketoconazole is a potent inhibitor of CYP3A4
catalysed metabolism of many known CYP3A4 probe drugs at inhibitor concentrations as
96
Discussion Chapter 4
low as 1 and 0.lpM (Newton et al., 1995; Baldwin et al., 1995; Sai et a1.,2000), although
CYP3A4-mediated diazepam oxidation is barely affected by ketoconazole concentrations
under 2pM (Sai et al, 2000). It has been shown that ketoconazole at low concentrations
(0.1-1pM) is highly specif,rc for CYP3A4, whereas higher concentrations can inhibit other
CYP450s (e.g. 5pM - CYPIAI) (Sai et al., 2000). Thus it is important to supplement
ketoconazole inhibition data with other identification approaches when the role of CYP3A4
is investigated in a metabolic reaction.
Quinidine is a selective CYP2D6 inhibitor, but it has been shown that at higher
concentrations it also inhibits CYP3A4 activity (Newton et al., 1995; Sai et al., 2000).
Since neither the antibody studies nor the expressed enzyme studies supported the
involvement of CYP2D6, and due to the lack of quinidine inhibition at 10pM, it can be
concluded that the inhibition seen with quinidine at 100pIVI supports the involvement of
CYP3A4.
CYP3A4 involvement in noroxycodone formation was further supported by the inhibition
seen in the presence of monoclonal antibodies directed against CYP3A4. The inhibition
was highly signif,rcant (p<0.001), and antibody-concentration dependency was found.
CYP3A4 expressed microsomes showed substantial noroxycodone formation, and the one
enzyme Michealis Menten model could be fitted to the data obtained from a kinetic study
in these microsomes. The Ky value (2.4mM) was within the range (1.52-l2.9mM) and
close to the median Kv value (2.9mM) obtained for noroxycodone formation inthe human
liver microsome kinetic studies, suggesting that CYP3A4 is the major enzyme involved in
liver noroxycodone formation. Furthermore, CYP3A4 involvement was supported by the
human liver microsome kinetic studies since no difference was seen in K¡a for the PM
compared to the EMs. Mortimer et al. (1990) showed that CYP3A4 activity is the same in
CYP2D6 poor and extensive metabolizers.
Expressed CYP2C19 supeÍsomes were able to form noroxycodone, and the formation was
more than 20 % of that observed for noroxycodone formation in CYP3A4 microsomes.
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Involvement of CYP2C19 was not supported by the chemical inhibitor studies as the only
inhibitor used against this isoform, S-mephenytoin, did not alter noroxycodone formation
signifìcantly. However, as described previously, it was sho\¡/n in CYP2C19 supersomes
that S-mephenytoin is not a very potent inhibitor of CYP2C19. Hutchinson (1999) found
that CYP2C19 is involved in the N-demethylation of hydrocodone. Similar to this study, S
mephenytoin did not have an effect on the N-demethylation reaction, while omeprazole,
another CYP2C19 inhibitor, inhibited the pathway significantly (20%). Since omeprazole
caused peak interferences in the HPLC chromatographs in the present study it could not be
used to determine CYP2CL9 involvement in noroxycodone formation.
Chloruoxazone (100¡rM) inhibited noroxycodone formation by 20 %. Lucas et al. (1999)
showed that this inhibitor is highly specific for CYP2El, although earlier studies have
suggested that CYP3A4 also is involved in chlorzoxazoîe metabolism (Gorski et al., 1997;
Shimada et a1., 1999). DDC (100pM) inhibition of noroxycodone formation was highly
variable and statistically insignificant. DDC has been used as an in vitro probe for
CYP2El, but several studies demonstrate that DDC has a low level of selectivity for
CYP2El, and that DDC at 100¡rM also inhibits the activity of various other CYP isoforms
(Chang et al.,1994; Eagling et al., 1998; Sai et al., 2000). Since the CYP2El antibodies did
not inhibit noroxycodone formation it was concluded that the inhibition observed with
chlorzoxazone and insignif,rcantly with DDC was due to CYP3A4 involvement.
The results of the solvent study were inconclusive for noroxycodone formation since the
inhibition seen for all the solvents was statistically insignificant, and since a wide range of
CYP450s are inhibited by all the used solvents.
Functional CYP isoforms are necessary for inhibition to be seen with specific chemical and
antibody inhibitors. It is assumed in the antibody and chemical inhibitor studies that all
CYP isofonns are functional in the microsomes. This assumption is reasonable for
CYP2D6 and CYP2C19 since all the livers had been tested for the respective activities.
However, the intrinsic isoform activities for the remaining isoforms are unknown. To by
pass this problem it would be necessary to incubate the microsomes with known CYP
specific substrates to confirm the isoform activity prior to the inhibitor studies. This
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involves many difficulties, such as obtaining probes and metabolites, as well as providing
the assays. The time frame of this study did not allow these comprehensive preliminary
studies.
The current study focused on oxymorphone and noroxycodone formation. However,
another unidentif,red peak was observed in the chromatographs. The retention time of this
compound was 8 minutes, which was slightly longer, but resolved from oxymorphone (7
minutes). The chemical inhibitor studies showed that CYP3A4 was involved in the
formation of this unidentified compound, but involvement of other enzymes than CYP3A4
could not be excluded since the peak was detected after oxycodone incubation with all the
tested expressed enzymes (CYP3A4, CYP2D6, CYP1A2, CYP2C19). Ishida et al. (1979)
characterized the metabolic pathways of oxycodone, and found that the oxidative
metabolites of oxycodone include noroxycodone, oxyrnorphone and noroxymorphone. The
chemical structure of oxycodone has no other readily oxidisable sites than that accounted
for with these three metabolites. It was confirmed that the peak was not norox¡rmorphone,
since noroxymorphone had a retention time of 4 minutes. It is suggested that the
unidentified peak is a metabolite of a contaminant in the oxycodone stock rather than a
metabolite of oxycodone itself, and that this contaminant elutes at a similar retention time
to oxycodone. To further characterise the unidentified peak it is necessary to investigate the
molecular structure of the compound. This could be calried out by using Mass
Spectrometry (MS) analysis after collecting the peak from the HPLC elution.
Cytochrome P450 is involved in the metabolism of many drugs, including oxycodone.
Knowledge of which CYP isoforms are involved in the metabolism of a drug is therefore
important in order to predict drug-drug interactions. Inter-individual variability in
metabolic activity is common for many CYP450 isoforms. Such variability can be due to
genetic or environmentally related differences in enzyme expression, and can influence the
clinical outcome of drugs metabolized by these CYP450 isoforms.
If the CYP isoforms involved in a drug's metabolism are characterized, it is possible to
estimate the likelihood for inter-individual variability in drug elimination. CYP3A4 is
subject to substantial inter-individual variability (Ball et al., 7999). This study showed that
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CYP3A4 was the main enzyrne catalysing oxycodone N-demethylation, arLd a l3-fold
variability in noroxycodone formation was seen. These in vitro studies indicate that
substantial variability in clearance and half-life of oxycodone may occur in vivo since the
N-demethylation pathway was important for the total intrinsic clearance of oxycodone.
However, the importance of N-demethylation for elimination of oxycodone in vivo has not
been fully investigated for humans. Further studies are therefore needed to determine the
percent contribution of different metabolic pathways for oxycodone in vivo.
There is considerable speculation on whether the O-demetþlation of oxycodone to
oxymorphone is important for the analgesic effect of oxycodone. The present study has
shown that CYP2D6 is responsible for most of the oxymorphone formation in CYP2D6
EMs, and that oxymorphone formation in a PM was almost 1/10 of that in EMs. It has been
shown for codeine that CYP2D6 PMs have less potent analgesic effect compared to
CYP2D6 EM (Sindrup et al., 1990). CYP2D6 PMs will have less potent analgesic effect of
oxycodone than EMs, if ox¡morphone formation is contributing in mediating the analgesic
effect of oxycodone. Further research is needed to investigate the relationship between




CYP2D6 proved to be the major enzyme involved in the O-demethylation of oxycodone,
but at least one other enzyme was responsible for a small fraction (4%) of oxymorphone
formation. CYPLAZ, CYP2Clg or/and CYP2E1 may be involved, but discrepancies were
seen between the different approaches for CYP identification. Other enzymes, not tested
for in this study, may contribute to the fcrmation of oxymorphone.
Alterations in oxymorphone formation may influence the analgesic effect of oxycodone if
oxycodone acts as a prodrug with oxymorphone as the active metabolite. CYP2D6
variability will alter oxymorphone formation significantly, and may therefore influence
oxycodone's effect. Variability in enzyme expression for the other CYP isoform(s)
involved in oxycodone O-demethylation is not expected to influence oxycodone effect
since the contribution to oxymorphone formation is minor. O-demethylation of oxycodone
is not important for its total clearance, and variability in activity of the enzyme(s) involved
in this pathway will therefore not influence the elimination of oxycodone in vivo.
The implications of oxycodone N-demethylation have been shaded by the interest in
oxycodone O-demetþlation. CYP3A4 involvement in N-demetþlation of oxycodone \ryas
confirmed in this study, and it was shown that noroxycodone formation is of major
importance for total intrinsic clearance of oxycodone. Although CYP3A4 was responsible
for the majority of oxycodone N-demetþlation, a minor involvement of CYP2C19 cannot
be excluded. However, if CYP2C19 is able to form noroxycodone, its contribution is very
small, and it is not likely to affect the clearance of oxycodone since CYP2CL9 only
comprise 1 % of the total liver CYP450 (Lewis et al., 1998).
The clearance via the CYP3A4 pathway varied 13-fold, and the variability in
noroxycodone formation between the different livers caused a high variability of the total
intrinsic clearance. Thus, variation in CYP3A4 expression is expected to influence
oxycodone clearance in vivo.
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CYP3A4 is involved in the metabolism of more than 50 o/o of all drugs (Benet et al., 1996).
Drug-drug interactions may therefore be important for oxycodone due to the importance of
CYP3A4 mediated N-demetþlation in the total clearance.
Some discrepancies were found between the different CYP identif,rcation studies. For
example, the chemical inhibition studies strongly supported CYPIA2 involvement, while
the antibody studies and the studies in expressed en4lmes showed no CYPIA2
involvement. This study has therefore demonstrated the need for several approaches when
determining CYP isoform involvement.
Oxymorphone formation was mainly catalysed by CYP2D6. Genetic polymorphism of
CYP2D6 is not likely to influence the clearance of oxycodone since the Odemethylation
pathway of oxycodone is minor. However, if oxymorphone formation is important for the
effect of oxycodone, a significant variability in analgesic response to oxycodone within a
population can be expected.
This study showed that CYP3A4 is the main enzyme involved in the N-demethylation of
oxycodone. It was also demonstrated that N-demetþlation is the quantitatively most
important pathway in the oxidative metabolism of oxycodone. Inter-individual variability
in CYP3A4 expression may therefore affect oxycodone elimination in vivo, and due to the
frequent involvement of CYP3A4 in xenobiotic metabolism, drug-drug interactions may be
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0 Substrate concentration (pM) 20000
Mchaelis-Menten two enzyme kinetics (1/y! weighting)
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Iteration count = 109
Sum ofsquares = 2.10165
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Iteration count = 28
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Mic.haelis-Menten two enzyme kinetics (1/y! weighting)
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0 Substrate concørtration ( pM) 20000
Michaelis-Menten one enzyme kinetics (no weighting)
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Iteration count = I 00 I
Sum ofsquares =213455
Standard deviation = 96.3362


























0 Substrate concentration (¡rM) 20000
Michaelis-Menten two enzyme kinetics (l/y! weighting)
ve locity=((Vmaxl t ubstrate)/(Km t +s ubs trate))+((Vmax2 t ubstrate)/(Km2+s ubs tr¿te))
Iterationcount=ll2
Sum ofsquares = 11.8449
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0 Substrate concentration 20000
Mchaelis-Menten two enzyme kinetics (l/y! weighting)
velocity=((Vmaxl t ubstrate)/(Km I +s ubstrate))+((Vmax2 t ubstrate)/(Km2+s ubs trate))
Iteration count= 118
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Michae lis -Mente n enzyme kinetics ( I /y we ighting)
velocity=Vmaxt ubs nate/(Km+s ubstrate)
Iteration count = 35
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0 S ubstrate concentration (¡rM) 20000
Mchaelis-Menten two enzyme kinetics (l/y! weighting)
ve locity=((Vmax I h ubs trate)/(Km I +s ubstrate))+((Vmax2tubs trate)/(Km2+substrate))
Iteration count=262
Sum ofsquares = 0.621 l0l
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ve locity=Vmaxt ubs tratel(Km+s ubs trate)
Iteration count = 40
Sum ofsquares = 4633.85
Standard deviation = 13.8952































0 Substrate concentration (pM) 20000
Michaelis-Menten two enzyme kinetics (1/y! weighting)
ve locity=((Vmax I t ubs trate)/(Km I +s ubs trate))+((Vmax2 t ubstrate)/(Km2+s ubs tra te))
Iteration count = 105
Sum ofsquares = 0.777792
Standard deviation = 0.188027
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Vmaxl 3.78772
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Mchae Iis -Menten enzyme kinetics (1 iy we ightin g)
velocity=Vmaxtubshate/(Km+s ubs trate)
Iteration count = 35
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Standard deviation = 3.96961




























0 Subshate concentration (pM) 20000
Michaelis-Menten two enzyme kinetics (l/y! weighting)
velocity=((Vmaxl t ubs trate)/(Km I +s ubstrate))+((Vmax2 t ubs trate)/(Km2+s ubs trate))
Iteration count= 103
Sum ofsquares = 13.5277
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Micha e lis -Mente n enzym e kinetics ( I /y we ightin g)
ve locity=Vmax*S ubs trate/(Km+s ubs trate)
Iteration count = 34
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CYP isoþrm specífic chemicøl inhibítors
Percent inhibition of NOC formation when OC concentration was similar to K¡aof OM:
n:4 (3 CYP2D6 EM and I PM)
Percent inhibition of OM formation when OC concentration was similar to Kvr of NOC:
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CYP isoþrm specìtìc chemícøl ínhíbítíors:
OM formation for ø CYP2D6 PM
Percent inhibition of OM formation in a PM:
Each bar represents the mean of a duplicate. Error bars show SD.
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